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Food allergy (FA) is a significant and often life-threatening health problem affecting 
about 4-6% of children and their families globally. In some developed countries FA 
prevalence has reached 10% and it is believed that developing economies may follow a 
similar trend since there is a reported rise in the global burden of other allergic diseases 
like asthma, allergic rhinitis and eczema. However, there is a dearth of population studies 
at global level documenting challenge-proven Ig-E mediated food allergy (FA) 
prevalence. As such, we studied an unselected population of children attending crèches 
in Cape Town, South Africa.  
Methodology 
All children aged 12-36 months attending the selected crèches between February 2013 
and October 2013 were eligible for the study. Participants were assessed with an allergy 
questionnaire, had skin prick tests (SPTs) done and if they qualified, were invited for an 
oral food challenge (OFC) at the Red Cross Hospital Paediatric Allergy Clinic (RCHPAC).  
The SPT wheal size results were categorised into ≥1mm, ≥3mm and ≥7mm. We gave a 
general description of the study sample with respect to the demographic characteristics 
and compared participants and non-participants. We reported sensitisation pattern 
towards foods in the panel i.e. egg white extract, peanut, cow’s milk, wheat (flour), soy, 
hazelnut and fish (cod) according to the SPT categories. The effects of age, ethnicity, sex 
and concomitant allergy on sensitisation patterns were assessed. Associations between 
the potential predictor variables and sensitisation were assessed by Z-test for 
proportions and Chi-square/Fisher’s exact.  
PART I presents the study protocol with a brief motivation for the relevance of the study 
and the methodology used. 
PART II presents a structured literature review on FA and FS in large populations of 
selected and unselected cohorts. It provides an overview of empirical evidence on 
prevalence estimates from both the developed and developing world, and the potential 
risk factors causing FA.   
v 
 
PART III summarises the methodology, results and interpretation of the analysis 
conducted in a journal-ready manuscript according to Current Allergy and Clinical 
Immunology Journal requirements. 
Results 
The sample consisted of; 39% black African, 20% Caucasian and 41% mixed race 
participants, with a median age 26 months (IQR: 22-31). Amongst 121 participants (66% 
response rate, 92% participation rate and 94% completion rate), the prevalence of 
SPT≥1mm to any food was 16%, SPT≥3mm 12% and SPT≥7mm 4%. The prevalence of 
challenge-proven Ig-E mediated raw egg allergy was 1.7% and peanut allergy 0.8%. Black 
African participants had higher sensitisation rates (23%) of SPT≥1mm to any food, when 
compared to Caucasian (13%) and mixed race (10%) participants despite the difference not 
reaching statistical significance (p=0.17).   
Conclusions 
This study was acceptable and feasible in this population that has a low prevalence of Ig-
E mediated FA that is comparable to other studies from developed countries using 
objective measures in unselected cohorts. The prevalence of FS is appreciably high in this 
sample and there are ethnic differences that require further investigation. The findings 
seem to suggest an existing burden of Ig-E mediated FAs in the South African context 
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A cross-sectional study of Ig-E mediated food sensitisation and food allergy 
in an unselected population of South African children aged 12-36 months. 
1 Protocol Executive Summary 
There is no reliable South African data on the prevalence of food sensitisation (FS) and 
challenge-proven Ig-E mediated food allergy (FA) in an unselected cohort of children who 
are believed to have the lifetime peak prevalence of FAs. Most of the studies done are on 
selected populations and report questionnaire or FS rates that are not true estimates of 
FA. Findings from these studies suggest high rates of FS in the selected populations and 
inter-ethnic differences in sensitisation and challenge-proven Ig-E mediated FA. There is a 
need to determine the current FS rates and the challenge-proven Ig-E mediated FA 
prevalence in an unselected sample of South African children aged 12-36 months and to 
ascertain possible inter-ethnic differences and the public health burden. 
This study of 114 children in the Cape Town Metropolis will lay a platform for the larger 
study of a total of 1200 children in Cape Town and 400 in the rural Eastern Cape. The 
immediate aims of the study are to determine the following: 
1. Prevalence of sensitisation and challenge-proven Ig-E mediated FA for the common 
food allergens (cow’s milk, egg, fish (cod), hazelnut, peanut, soya and wheat. 
2. Pilot the questionnaires that will be used for the participants and non-participants.  
3. Explore some risk factors as potential predictors of FS and Ig-E mediated FA. 
The participants will be recruited from Cape Town crèches and data will be collected via a 
participant allergy questionnaire and a non-participant questionnaire will be used to 
assess for participant selection bias. Data on demographics and risk factors will be 
gathered and skin prick tests (SPT) performed. FS will be recorded based on degrees of 
sensitisation viz SPT≥1mm, SPT≥3mm and SPT≥7mm while Ig-E mediated FA will be 
defined as a positive SPT (SPT≥1mm > the negative control) and a positive oral food 
challenge (OFC). Rates of sensitisation and challenge-proven Ig-E mediated FA to foods 
under review will be computed and analysed based on particular risk factors. 
 





2.1 Background  
FA has over the years become an issue of public health importance with evidence of an 
increasing prevalence (1). This rise in prevalence has however lagged behind by decades 
to the initial rise in respiratory allergies. Studies in westernised countries have reported 
remarkable statistics like a three-fold increase in peanut and tree nut allergy between 
1997 and 2008 from a United States of America (USA) survey (2) and a two-fold rise in 
peanut allergies in the United Kingdom (UK) over the last 10-15 years (3). However, in the 
UK (Isle of Wight) the follow-up study shows that peanut sensitisation and reported 
allergy has since plateaued (4). The increasing concern over FAs is based on the fact that 
it has been shown to significantly affect morbidity, mortality and quality of life (5).  
2.1.1 Global estimates of food allergy 
Many countries do not have accurate prevalence data for global estimates. Most 
prevalence measurements are based on self-report or surveys that are not based on 
objective confirmation of allergy through OFCs (6). Estimates from studies in developed 
countries using objective measures suggest that up to 2.5% of the adult population has FA 
with higher rates of up to 10% being reported in the first 3 years of life (7,8). A study in 
the UK followed birth cohorts from 2001-2002 to determine the incidence of confirmed 
FA and reported rates of 4%, 2.5% and 3% at 12 months, 2 years and 3 years respectively 
(9,10). A Danish study of an unselected population of children and adults showed the 
prevalence of challenge-proven FA to be 2.3% in children <3 years and 1% for children >3 
years (11). 
More recently in Australia, a large cross-sectional study assessing 2848 infants aged 12 
months showed appreciably high levels of FS and challenge-proven Ig-E mediated FA 
using predetermined OFC criteria. The initial results show FS rates of 8.9% for peanuts 
and 16.9% to raw egg white. Overall, more than 10% of the infants have proven Ig-E 
mediated FA to one of the common allergenic foods of infancy (12).  




2.1.2 Food allergy in Southern Africa 
In Africa there is scarcity of data on the prevalence of FA possibly because much focus is 
on communicable and adult onset non-communicable diseases while allergic disorders 
are regarded as less important. Most of the studies available are from selected 
populations and questionnaire based surveys (13). 
 
In Gaborone, Botswana, 55 patients from an allergy practice suffering from eczema, or 
those who had a history consistent with FA underwent testing for FS. Children with 
atopic dermatitis (AD) were mostly sensitised to egg (11%) and peanut (7%) (14). A case-
control study in Pretoria checking for co-morbid conditions in 100 asthmatic children 
reported the following FS rates; 9% peanuts, 7% egg white, 4% wheat, 4% fish and 3% milk 
(15). In Cape Town, a cohort of 400 allergic children showed sensitisation to be common 
in eczematous children with an overall prevalence of 13%. Most sensitisation was with 
peanuts 35%, egg white 30%, milk 17%, fish 4%, tree nuts 3% and potato 3% (16). 
 
In a multi-country study, the Early Prevention of Asthma in Atopic Children (EPAACTM), a 
heterogeneous group of South African infants aged 12-24 months showed high levels of 
sensitisation (not challenge-proven allergy) towards egg (47.1%), cow’s milk (28.4%) and 
peanut (26.8%) (17). Gray et al assessing the prevalence of FA in children with Atopic 
Dermatitis (AD) observed high rates of sensitisation and challenge-proven allergy in black 
African and mixed race participants. Overall, FS level was at 66% and the confirmed FAs 
were 42% showing inter-ethnic differences in the South African context (18). In an 
unselected sample of black African high school students in Cape Town, 5.4% showed 
positive SPT towards the common food allergens. The prevalence of the reported 
allergens was 3.3% egg, 1.9% peanut and 1.9% milk (19).  
 
The findings from the studies in selected populations suggest that there is appreciable 
sensitisation and confirmed FA towards the common food allergens in the local context. 
There are no studies in South Africa on unselected populations to help understand the 
prevalence of FAs in relation to global estimates. 




2.1.3 Food sensitisation versus food allergy 
In the EPAACTM study the South African overall level of sensitisation was 26.8% which was 
higher than the estimate for the whole group, 24.4%. The South African level of peanut 
sensitisation was higher (7.2%) than the rest of the group (4.9%). Despite such high FS 
rates, the prevalence of proven peanut allergy in South Africa is reportedly low. It stands 
to reason that the 95% positive predictive value (PPV) cut-offs for SPT values used in 
predicting positive food challenges may not be applicable in the South African context 
(17). 
Based on anecdotal evidence, FA is believed to be uncommon especially in the black 
South African population (20,21). Should the prevalence be shown to be high in this 
population, it may provide some clues to the factors which could be driving the FA 
epidemic in the local context.  
2.2 Rationale  
There is evidence indicating that the prevalence of FA maybe much higher in the urban 
black African population than anticipated (19). The ethnic diversity in South Africa and 
the rapid urbanisation taking place in the indigenous black South African population may 
have an influence on the increase in FA as a result of the lifestyle differences (18). To 
avert missing children with a potential for challenge-proven Ig-E mediated FA, we will use 
any level of sensitisation (SPT ≥1mm) to denote positivity toward the allergen being 
tested and such subjects will undergo an OFC if they are not tolerating the food(s) on 
clinical history.  
A SPT≥3mm traditionally supports a diagnosis of Ig-E mediated FA with a good clinical 
history however, the SPT level has a low specificity (about 50%) to be of value in 
identifying clinically relevant FA. As a result we will also incorporate the category 
SPT≥7mm since for many of the foods that have been studied, a magnitude of skin prick 
test in this range has been shown to be associated with a positive outcome on 
incremental OFCs (22,23). We will denote the three categories; SPT≥1mm, SPT≥3mm and 
SPT≥7mm to represent low, medium and high levels of sensitisation. All SPTs are 
“corrected” for the negative control being 0 mm. 




Most FA occurs in the first three years of life (24,25) we will therefore determine the Ig-E 
mediated FA prevalence in children aged 12-36 months to ascertain the possible public 
health burden. The findings can be used for advocacy regarding the provision of health 
services and food alternatives for the affected children and their families (26). Local 
studies have highlighted the need to evaluate the validity of the current cut-off values for 
the prediction of SPT and blood specific Ig-E levels in black South African children (18). 
This study will as well lay the platform for prediction studies and provide initial insights 
into modifiable and non-modifiable risk factors associated with FAs in South Africa. 
2.3 Study objectives 
This study will be conducted in the crèches located in the Cape Town Metropolis. The 
primary objective of the study is to determine the prevalence of sensitisation and 
challenge-proven Ig-E mediated FA in this sample that is presumed representative of the 
Cape Town population.  
The following objectives are outlined for the study:  
1. To determine the sensitisation levels to any one or more of the 7 common allergic 
foods (hen’s egg, cow’s milk, peanut, tree nuts, soy, wheat and fish (cod)). 
2. To determine the challenge-proven prevalence of Ig-E-mediated FA to the above 
mentioned food allergens. 
3. To explore the patterns of particular risk factors as possible predictors of FS and Ig-E 
mediated FA. 
3 Methodology 
3.1 Study design and setting 
This is a cross-sectional (prevalence) study to be conducted at crèches in different areas 
of Cape Town and the OFCs will be conducted at the Red Cross Hospital Paediatric 
Allergy Clinic (RCHPAC). 




3.2 Population and recruitment 
The study population will be children aged 12-36 months attending crèches in the Cape 
Town Metropolis. This age group is notoriously difficult to access via child health clinics 
as their last scheduled post-natal visit is at 18 months. Therefore recruiting from the local 
registered crèches we will have a better age representation of those up to three years. A 
list of registered crèches in Cape Town is overtly available online and permission was 
obtained (Levin M 2012, personal email, July 11) from the Department of Social 
Development (DSD) to approach crèches to participate in the study. 
Crèches selected from the sampling frame (using Microsoft Excel number generator) will 
be contacted and permission obtained from the manager/principal to conduct the study. 
Parents of eligible children will be sent an information leaflet regarding the study and will 
be invited to attend the crèche on study days as arranged with the crèche management. 
On study days, the team will meet with parents/guardians and details of the study will be 
discussed using an interpreter if necessary. If they choose to participate, informed 
consent will be obtained from the legal guardian in their language of choice. They will 
complete the study questionnaire, their child will be physically examined and undergo a 
SPT. In some cases SPT may be deferred to another day if the child has recently taken 
antihistamines. Furthermore, all children with a recent history (<6 months) of a reaction 
to any of the foods tested for will have their SPTs performed at the RCHPAC.  
3.2.1 Inclusion criteria 
 Children in the age range 12 months to 36 months. 
 Children for who informed consent can be obtained from the parent or legal 
guardian. 
3.2.2 Exclusion criteria 
 Children with significant chronic illnesses (apart from that related to their atopic 
predisposition, such as asthma).  
 Unwillingness or inability to comply with study requirements or procedures including 
the oral food challenge. 




3.3 Sample size 
The sample size is calculated using an expected proportion of 8% for challenge-proven Ig-
E mediated FA to any particular food type. This is based on the primary study objective 
which is to determine the prevalence of challenge proven Ig-E mediated FA. Since there 
is no previous local data on the prevalence of confirmed allergy in an unselected 
population we assumed the expected proportion based on the preliminary results of the 
largest and most recent FA prevalence study (Australian HealthNuts Study (AHNS)) that 
has reported the prevalence of challenge-proven Ig-E mediated FA to be 10% (12). 
 
We do not forsee our prevalence to be as high as 10% since we expect the incidence of FA 
to be reducing by the age of 36 months. The correlation between Ig-E mediated FA/FS 
outcome and the predictor variables will not be explored in-depth in the first phase of 
the study because of a possible lack in precision. The associations will be considered in 
the subsequent phases of the study, as such the risk factors will not be considered in the 
sample size calculation. In this phase of the study we seek to have a preliminary 
understanding of the association between some of the predictor variables that could be 
driving the allergy epidemic in this population and the Ig-E mediated FA/FS outcome.  
 
In addition to the expected proportion we will use a precision of 5% and a power of 80%. 
 
Assuming a challenge-proven Ig-E mediated FA proportion of 8%: 
 
The sample size = {0.08(1-0.08)1.962}/0.052 = 113.1 = 114 
3.4 Data collection tools 
3.4.1 Questionnaire  
A participant questionnaire will be completed with a study team member going through 
all the questions and collecting information on demographics and potential risk factors 
for FA with the parent/caregiver in their preferred language. Non-participants will be 
asked to fill in the non-participant questionnaire to assess for participant selection bias.  




3.4.2 Skin prick testing 
SPTs will be performed by trained medical/nursing staff. Children with no history of a 
reaction to food will have their SPTs performed at the crèche. Those with positive SPT 
(≥1mm > the negative control) will be invited to the RCHPAC for OFCs. Children who have 
a history of a reaction to food will have both their SPT and OFC performed at RCHPAC. 
Standardised solutions from ALK Abello (Thermo FisherTM) and ALK lancets will be used 
for the following food allergens: egg white extract, cow’s milk, soya, wheat (flour), fish 
(cod), peanut, hazelnut, positive control and negative control. Sensitisation will be 
recorded based on the following SPT categories (> the negative control); SPT≥1mm, 
SPT≥3mm and SPT≥7mm. 
3.4.3 Oral food challenges 
In cases where there is evidence of any sensitisation to the foods being tested for (SPT≥ 
1mm > the negative control), and there is no clear history of a recent severe allergic 
reaction to the food(s), and no clear history of tolerance, an incremental food challenge 
will be arranged. If children are sensitised to more than one allergen, they will need 
multiple food challenges on different days with an appropriate time interval between 
challenges.  
3.5 Reliability and validity 
The questionnaire was developed following the examples from the ongoing AHNS (27). 
This will serve as a comparing mechanism that will ensure validity in the tool we are using 
to collect data. Since this is the first phase of the larger study, the reliability of the data 
capturing tool will be assessed at the end of the first phase of the study and if need be, 
the questionnaire will be refined and re-conceptualised so that it measures what it is 
assumed to be measuring (22). 
3.6 Potential study biases 
There is the possibility that parents who have a concern that their child might have FA 
are more likely to choose to participate and complete the study than those without such 
a concern.  




In an attempt to account for this bias we will ask parents who decline to participate if 
they would agree to complete a short non-participant questionnaire with questions 
regarding their child’s allergy history.  
There is also the possibility of misclassifying participants based on their clinical history i.e. 
those with a suspect allergy history are more likely to be classified as sensitised when 
reading the SPT measurements. To minimise on this we will rely on the judgement of 
another team member not performing the SPT to confirm the measurement. There will 
be continuous training as well to help reduce measurement errors in variables.  
3.7 Measurement 
The main outcomes of interest are the number of participants sensitised/truly al lergic to 
a particular food as a proportion of the study sample. Using particular risk factors 
(ethnicity, age, sex and concomitant allergy status) we will determine the different 
proportions of participants that are either sensitised/truly allergic.  
Table 1.1: List and definition of variables that will be considered in the study 
Name/Type Scale Possible Values 
Age Numerical - continuous 12 – 36 months 
Sex Categorical - binary Male, Female 
Ethnic origin Categorical - nominal Caucasian, Mixed race, Black African 
Food exposures Categorical - binary Yes, No 
Reactions to foods Categorical - binary Yes, No 
Reaction Doctor diagnosed Categorical - binary Yes, No 
Self-reported Asthma/Hayfever/Eczema status Categorical - binary Yes, No 
Diagnosed made by Categorical - nominal Self, Doctor,  Nurse 
Clinical confirmed Asthma/Hayfever/Eczema status Categorical - binary Yes, No 
Family member history of allergic disease  Categorical - binary Yes, No 
SPT result Numerical - continuous  ≥0mm 
SPT≥1mm, ≥3mm & ≥7mm Categorical - binary Yes, No 
Child tolerant to food if SPT≥1mm Categorical - binary Yes, No 
Oral food challenge indicated Categorical – binary Yes, No 
Oral food challenge result Categorical - nominal Positive, Negative, Equivocal 
  




3.8  Potential benefits of study participation 
Potential benefits of positive allergy tests/OFC include a conclusive diagnosis of Ig-E 
mediated FA demonstrating the need for counselling in strict avoidance of the food, 
reduction of the risk of inadvertent exposures, reduction of anxiety about the unknown, 
and validation of the child’s family’s efforts to avoid a food. The benefits of negative 
allergy testing/OFC are reassurance, expansion of the diet, improvement of the child’s 
nutrition and quality of life.  
4 Data management and analysis plan 
Data will be collected by study personnel and recorded in participant questionnaires for 
entry into a Microsoft Access database for storage. The data will be cleaned using 
Microsoft Access pivot tables and exported to STATA version 11.1 (Stata Corp. College 
Station Texas) for analysis. Raw data will be stored in a specified locked cupboard in the 
Child Health Allergy Department at Red Cross War Memorial Children’s Hospital and only 
the Principal Investigators and named study staff will have access to it. Each participant 
will be assigned a unique study number. The Microsoft Access database will only use the 
study number and not the name or hospital number.  
The correlation between study number and respective name will be kept on a separate 
Microsoft Excel database to which only the study staff will have access. Confidentiality 
will be maintained at all times in the study and the name, hospital number, address, 
telephone number, or any other direct personal identifiers will not identify the 
participant in the study records, except when required by law. The data collected 
remains the property of the University of Cape Town. 
Basic descriptive statistics of the sample will be reported i.e. age, sex and ethnic 
distributions. For each participant we will also report the history of allergic diseases for 
the first degree relatives (i.e. parents and siblings). 
4.1 Objective 1 
We will report the number of participants for particular SPT category (i.e. ≥1mm, ≥3mm 
and ≥7mm) as a proportion of the study sample for each of the foods tested.




4.2 Objective 2 
For the participants who undergo OFCs, we will report the number of those who are 
positive for the food tested as a proportion of the study sample.  
4.3 Objective 3 
In order to examine the association between particular predictor variables and the Ig-E 
mediated FA/FS outcomes, we will examine the patterns of sensitisation by ethnicity, 
age, sex and concomitant allergy using Pearson chi-square tests and Z-test for 
proportions, Kruskal Wallis and Wilcoxon rank-sum tests to compare medians for 
numerical variables. We will also report the number of participants with self-reported 
food allergies, self-reported concomitant allergy and clinical confirmed concomitant 
allergy as a proportion of those with any sensitisation (SPT≥1mm > the negative control).  
5 Ethical considerations 
5.1 Consent 
All parents/legal guardians will be required to give consent prior to entering the study. 
Consent will be taken in the caregiver’s language of choice and the consent forms will be 
available in English, Xhosa and Afrikaans. Consent will cover all aspects of the study, 
including taking a dietary and allergy history, performing SPTs, performing the food 
challenges if indicated, and for data collection and reporting. We will also take consent 
for the taking of blood, stool and house dust samples from participant parents where 
these tests are indicated for further research. 
The consenting process will consist of a detailed verbal description of the study as well as 
a written consent form and information sheet. If required, a trained translator will assist 
with the interpretation. Consent forms will be in triplicate, with one copy for the family, 
one for the study personnel, and one for the study folder.  




5.2 The primary ethical issues in this study 
5.2.1 Risks related to skin prick tests  
A SPT can cause sensitisation and also acute allergic reactions theoretically, including 
anaphylaxis but both are extremely rare. In a recent Swedish study that reviewed 
findings from a sample of 5908 children <18 years undergoing SPTs found that 0.0024% 
had a reaction and 0.12% had a generalised reaction mostly involving the skin only. 
Children <1 year and those with eczema were more likely to have a reaction whereas 
older children mainly had vasovagal reactions. There were no severe anaphylactic 
reactions and only 2 of the 14 participants who had a reaction required adrenaline but no 
further treatment (28). 
Experience at the RCHPAC reflects the Swedish study experience where the most 
common reactions are itching and burning at the test site which is easily treated with 
antihistamines. These reactions are short lasting and can be relieved with oral 
antihistamine and topical cold compress (Levin M 2013, Paediatric Allergy Clinic report, 
November 28). 
5.2.2 Risks related to oral food challenges  
When introducing increasing amounts of allergen there is potential of allergic reactions 
of varying severity. Most allergic reactions during food challenges are mild and respond 
promptly to appropriate medical therapy e.g. short acting antihistamines. The more 
severe reactions (including lower respiratory and cardiovascular reactions) will require 
treatment with intramuscular adrenaline (29). 
A large retrospective review showed that 28% of children had a severe reaction. These 
however, were all respiratory with no cardiovascular or anaphylactic reactions, and all 
responded to antihistamines, adrenaline, β-agonists and corticosteroids with no need for 
hospitalisation (29). The RCHPAC having performed over 120 OFCs in the last 2 years has 
had no severe reactions including anaphylaxis, and no one required adrenaline or 
hospitalisation (Levin M 2013, Paediatric Allergy Clinic report, November 28). 
 




To minimise risk of morbidity associated with food challenges, they will be performed 
under medical supervision in a hospital setting with resuscitation facilities, and according 
to a standardised protocol with slowly increasing doses and adequate intervals between 
doses. 
5.2.3 Risks related to venipuncture  
As venipuncture may be painful, a local anaesthetic cream will be used prior to drawing 
blood. In order to minimise the risk of infection all standard sterile procedures will be 
followed.  
6 No fault insurance 
The participants in this study are covered by the no-fault insurance offered by the 
University of Cape Town. The participants’ parents or guardians will be informed of this 
during the consenting process and it is specified in writing on the information sheets.  
7 Funding 
The bulk of the funding for the study is being obtained by the Principal Investigator 
mainly from grants. 
8 Dissemination of study findings 
Given the objectives of the research, the findings will robustly assess the FS rates and the 
prevalence of challenge-proven Ig-E mediated FA in the Cape Town sample. These 
findings will be used to inform the larger study involving a cohort of children from the 
Cape Town Metropolis and Bulungula area in the Eastern Cape. 
The immediate beneficiaries of the information are the participants and the family 
members of the participants. Findings will be disseminated in the form of a preliminary 
report, seminars in the School of Public Health, UCT and presentations at appropriate 
meetings and conferences. An article will be submitted to a public health/paediatric 
allergy/clinical immunology peer-reviewed journal.   





Provisional enquiries have indicated that there are on average 10 children aged 12-36 
months per crèche. We aim to visit 1-2 crèches per week (averaging 10 participants per 
week) and depending on the response rate (assumed to be at 60-80%) the data collection 
for the study is likely to be completed within 9 months (February 2013-October 2013). 
This time frame takes into consideration factors like delayed responses from the crèches 
and slow recruitment rates amongst other challenges that could be encountered as the 
study progresses.  
 An outline of the proposed study time is given below: 
February 2013-October 2013 Data collection 
November 2013-December 2013 Data capturing and cleaning 
January 2014 Data validation and Baseline data exploration 
February 2014-March 2014 Final analysis, preparation of manuscript 
April 2014 Submission 
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2. Literature Review 
1. Introduction 
1.1 Definition of food allergy and food sensitisation 
The term food allergy (FA) is used to describe adverse reactions to foods mediated by 
the immune system, and non-allergic food hypersensitivity to describe those not immune 
mediated. Food hypersensitivity (FHS) represents the umbrella term for both reaction 
patterns (1,2). FA is specifically defined as an adverse immune reaction arising from a 
specific response that occurs reproducibly on exposure to a particular food (3). The 
individuals with such allergies are therefore at risk of developing life-threatening Ig-E 
mediated systemic reactions upon ingestion of the particular allergen (4).  
Food sensitisation (FS) is the production of a particular type of allergic antibody (Ig-E) to 
a particular food by the immune system resulting in a positive allergy test (Skin Prick Test 
(SPT) or immunoCAP). It is possible for a person to be sensitised without experiencing an 
adverse reaction upon food ingestion (3). 
Figure 2.1: Terms used for adverse food reactions and examples 
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1.2 Clinical signs and symptoms of food allergy 
The symptoms of Ig-E mediated FA vary, ranging from mild discomfort to life threatening 
reactions that require immediate medical attention. Symptoms may involve many body 
systems but usually they are localised in the GIT, the skin/mucous membranes, the 
respiratory tract and/or the cardiovascular system. Adverse food reactions may occur 
within a few minutes to an hour after ingestion and can last for days to even weeks (5). 
1.3 Consequences of having food allergies 
Those found to have lg-E mediated FA have their quality of life altered in a negative way. 
The sufferers and the family have to deal with the disbelief concerning their condition 
and face the challenges of managing their day to day lives. Food avoidance is challenging 
and subjects may need to alter their habits, limit their activities and organise special diets 
during social events, communal activities and during hospitalisation. There is a risk of 
severe reactions and patients often experience increased anxiety leading to social 
isolation and possible mental health problems (6,7).  
2. Background 
2.1 Common allergenic foods 
There has been a steady increase over the past decades in the understanding of FA, but 
epidemiological knowledge about causes and determinants is still limited (8). At global 
level, the foods commonly associated with Ig-E mediated reactions in children <5 years 











Table 2.1: Reported allergenic foods in various geographical regions 
Adapted from Boye (10) and Prescott et al. (9). 
GEOGRAPHICAL 
REGION 
COUNTRIES ALLERGENS REPORTED IN THE 
UNDER 5 YEARS POPULATION 
REFERENCE 
Asia China, Hong Kong, Korea, 
Japan, Singapore, Thailand, 
Philippines, Taiwan, Indonesia 
and Malaysia 
Shellfish, egg, peanut, beef, cow’s 
milk, fruit, treenuts, soy, shrimp, 
wheat, fish, rice, crab, sesame, 
pork, seafood, peach, crustacean, 
prawn and buckwheat. 
(11-18) 
Middle East Saudi Arabia, Israel, Lebanon, 
Iran 
Peanut, egg, cow’s milk, wheat, 
banana, fish and sesame.  
(19,20) 
Africa South Africa Peanut, egg and cow’s milk  (21) 
Oceania Australia Dairy, egg, peanuts, cashew nut, 
tree nuts, cow’s milk, fish, 
seafood and mango/lemon drink. 
(22,23) 
North America Canada and USA Seafood, nuts, tree nuts, 
strawberry, wheat, soy, cow’s 
milk, shellfish and peanuts. 
(24-26) 
Central & South 
America 
Mexico, Colombia and Brazil Dairy, egg, fish, shrimp, beans, 
soy, milk, seafood, orange, chilli, 
beans, mango, cacao, corn, 
vegetables, wheat, and shellfish  
(27-29) 
Nordic Countries Denmark, Norway, Iceland, 
Sweden and Finland 
Egg, cow’s milk, peanut, fruits, 
vegetables, fish, nuts, cereals, 
wheat, soy and tree nuts,  
(30-35) 
Western Europe UK, Germany, Switzerland, 
Greece, Poland, France, Spain 
Egg, cow’s milk, peanut, tree nuts, 
fish, wheat, soy, hazelnut, potato, 
fruits, meats and legumes 
(35-38) 
Central Europe Turkey, Lithuania and Slovenia Cow’s milk, egg, wheat, beef and 
peanut 
(35,39) 




2.2 Global food allergy prevalence 
There appears to be a gradual increase in the prevalence of allergic diseases globally in 
both developed and developing countries with 30-40% being affected by one or more 
allergic diseases. Of those affected by allergic diseases, almost 10% are estimated to be 
food allergic. In Europe, about 11 -26 million people suffer from FA (40). When projecting 
this estimate onto the world population of 6.6 billion, it translates to 220-250 million 
people suffering from FA (41). Besides the increasing incidence, the severity and 
complexity of FA is also increasing (Figure 2.2) (42). 
FIGURE 2.2: Country specific cases of fatal food induced anaphylaxis (42) 
 
The use of extrapolation to determine FA prevalence poses challenges because self-
reported symptoms of food reactions are far more perceived (20–30%) than proven (2–
8%) (33,43). A meta-analysis by Rona et al found self-reported FA to range between 3% 
and 35% for any food. When the studies were analysed under sensitisation and clinical 
symptoms, and food challenge categories, the prevalence was lower at 2-5% and 1-10.8% 
respectively, showing that self-reported reactions are not true FA (44). 
 




It is difficult to estimate worldwide prevalence because of deficiency in data at 
regional/country level. Factors making comparison of existing regional/country data 
difficult include: 
 Selection bias: studies either include selected or unselected populations. 
 Differential attrition levels across studies: low participation/response rates. 
 Frequency of evaluations: allergy may resolve or develop in-between. 
 Inconsistent definitions of FA: self-reported symptoms, sensitisation, sensitisation 
with a positive history, sensitisation with a convincing history or food challenge 
proven (and different types of challenges). 
 Data analysis: handling of missing data and no sensitivity analysis. 
 Foods targeted have different natural history. 
 FA severity: whether to include the responses (mild, moderate or severe). 
 Study design and size: costs and accuracy (45). 
Despite these methodological/measurement challenges the prevalence in children and 
adults varies between 4-6% and 1-3% respectively showing a greater burden in children 
(36,46).  
3. Literature search strategy 
This review focuses on the prevalence of Ig-E mediated FA or FS in different regions 
worldwide and the potential risk factors. To identify the relevant manuscripts to be 
included, Pubmed, Scopus (Embase), Ebsco Host and Google Scholar searches were 
undertaken for studies conducted since 1993. 
The keywords used included “prevalence or incidence”, “epidemiology”, “food allergy” 
or “food sensitisation” or “food hypersensitivity”, “infants” and “children”, “skin prick 
tests” and “oral food challenges” and “risk factors” or “predictors”. 
After screening with the keywords and the abstract or the text, the article was examined 
to determine inclusion into the literature review. Included articles were published 
between the years 1993 and 2014. The reference lists of these articles were also reviewed 
for additional studies. 




 For global prevalence data the following inclusion criteria was used: 
 Large population based studies in unselected children populations. 
 Ig-E mediated FA/FS prevalence rates based on the report of either self-
reports/expert screening + evidence of confirmatory tests – sensitisation i.e. specific 
food lg-E/SPT, clinical symptoms + oral food challenge (OFC) or double blind placebo-
controlled food challenges (DBPCFC). 
Because of paucity of high quality data in unselected populations in Sub-Saharan Africa, 
criteria were relaxed to include selected and unselected populations of any size that had 
confirmatory tests. For the risk factors general associations that have been observed in 
literature were reported. 
4. Prevalence in the developed countries 
The prevalence of challenge-proven FA in developed countries is estimated to affect 
from 1-2% to 10% of the population, with cumulative incidences of 3-6% (45,47,48). There 
appears to be evidence for FA escalation in these countries such as an almost four-fold 
increase in peanut allergy over the past decade in USA children (49) with similar rates 
being observed also in UK and Australian children (50-52). However, stabilisation in 
prevalence rates like the plateauing peanut sensitisation and reported allergy in the Isle 
of Wight (UK) have also been reported from these regions (53).  
4.1 United States of America 
It is believed that 3.5-4% of the population has lg-E mediated FA (54). In 2005–2006, the 
National Health and Nutrition Examination Survey (NHNES) reported the overall 
prevalence of clinical FA to be 2.5% based on specific serum Ig-E levels (sIgE) with the 
highest prevalence of 4.2% being observed in those 1-5 years (55). A survey in 2007 








Table 2.2: Summary of food allergy prevalence from population-based studies  
Adapted from Prescott et al. (9) and Kung (57). 
LOCATION 
(PUBLICATION YEAR) 
STUDY SIZE METHODOLOGY AGE OF 
PARTICIPANTS 
OVERALL (%) REFERENCE 





3.9 in children 
      (55) 




0-17 years 8                             
0-2 years: 6.3        
3-5 years: 9.2 
(24) 
Europe (2007) Meta-analysis 
(51 studies) 
multiple Infants and 
adults 
1-10.8        (44) 
Europe (2014)  Meta-analysis 
(30 studies) 
multiple Infants and 
adults 
SPT: 2.7          
proven: 0.9 
       (58) 
UK (1994) 7500      
households 
self-report & DBPCFC Infants and 
adults 
self-report: 20.4 
proven: 1.4-1.8    
6-8 children 
       (43) 
UK (2006 & 2008) 969 OFC 1 and 2 years 2.8 & 2.5        (36,59) 
Denmark (2009) 562 OFC <5 years 1.2-3.6 (30) 
Sweden (2001) 273 SPT & sIgE 2 years 7 (60) 
Sweden (2008) 2563 sIgE 4 years 15 (34) 
Norway (2009) 512 SPT & DBPCFC 0-2 years 6.8 (61) 
Norway (2012) 353 SPT & sIgE 2 yeas 18.7 (62) 
Iceland (2011) 1341 SPT & DBPCFC 0-1 years 2 (31) 
Australia (1997) 620 OFC 2 years 1.18 (63) 
Australia (2011) 2848 Food challenges 1 year 10 (23) 
China (2011) 497 Food challenges 0-1 year 3.8 (11) 
China (2012) 1604 Food challenges 0-2 years 5.5-7.3 (64) 
Taiwan (2012) 30018 self-report & SPT/IgE children and 
adults 
<3 years: 3.44       (13) 
Thailand (2012) 546 SPT & Food 
Challenges 
2-7 years 1 (12) 
Thailand (2005)  656 SPT & Food 
Challenges 











In a review by Nwaru et al, the overall pooled point prevalence (higher in children than 
adults) and the lifetime prevalence (similar in children and adults) of self-reported FA 
were 5.9% (95% CI: 5.7–6.1) and 17.3% (95% CI: 17.0–17.6) respectively. The point prevalence 
of sensitisation (higher in children than adults) to ≥1 food as assessed by sIgE levels and 
SPT was 10.1% (95% CI: 9.4–10.8) and 2.7% (95% CI: 2.4–3.0) respectively. OFC/DBPCFC 
positivity (similar in children and adults) was 0.9% (95% CI: 0.8–1.1).The incidence of FA 
appears to be consistent over time, however there is evidence suggesting that the 
prevalence may be increasing (53,58).  
LOCATION 
(PUBLICATION YEAR) 
STUDY SIZE METHODOLOGY AGE OF 
PARTICIPANTS 
OVERALL (%) REFERENCE 
Israel (2002) 9070 food serum IgE + 
clinical symptoms 
0-2 years 1.2 (19) 
 
Zimbabwe (2003) 14000 & 50 
for Sub-study 
expert screening & 
SPT & ImmunoCAP 
1-63 years 10       (66,67) 
Ghana (2010) 1431 self-report & SPT 5-16 years 5       (68) 
Botswana (2009) 55 history & SPT Children and 
Adults 
14.5       (69) 
South Africa       
Cape Town (2008) 
220 SPT Teenagers 5.4        (70) 
South Africa 
Pretoria (2007) 
100 SPT 2months - 
20 years 
9/7        (71) 
South Africa  
Bloemfontein (2002) 
771 slgE 3 months - 
15 years 
24.4/9.5       (72) 
South Africa        
Cape Town (2008) 
400 SPT & slgE children 13       (73) 
South Africa 
Johannesburg (1997) 
468 SPT 1 month - 18 
years 
30.4/18.2       (74) 
South Africa (2009) 161 slgE 12 - 24 
months 
47/28.4       (75) 
South Africa       
Cape Town (2012) 
100 multiple children 42      (21) 





A cohort study by Hill et al reviewed FA development in 620 infants at risk of developing 
atopic disease and extrapolated to a random community population. At 2 years follow-up 
the overall prevalence of challenge-proven allergy was 1.2%. Particular food specific 
sensitisation rates were; 3.2% egg, 2.0% cow’s milk, 1.9% peanut, 0.2% wheat, 0.1% soya, 
0.2% hazelnut and 0.1% fish (63).  
The Australian HealthNuts Study (AHNS) assessed the prevalence of common Ig-E 
mediated FA in 2848 infants aged 12-months and overall, over 10% of the infants had 
challenge-proven IgE-mediated FA to one of the common allergenic foods of infancy. 
High levels of sensitisation to peanuts 8.9%, raw egg white 16.5%, cow’s milk 5.6%, sesame 
2.5% and shellfish 0.9% were reported. Challenge proven allergy prevalence was 3.0% (95% 
CI: 2.4-3.8) for peanut, 8.9% (95% CI: 7.8-10) for raw egg and 0.8% (95% CI: 0.5-1.1) for 
sesame (23). 
5. Prevalence in developing and emerging economies 
In many developing countries and emerging economies (like China, India and Brazil) 
there continues to be little epidemiological data on FA and FS. Currently it is assumed 
that the prevalence rates are low but this raises uncertainties about the potential health 
impacts should these assumptions not be supported by evidence (10). 
5.1 China 
In Chongqing, mainland China, an unselected population of 497 infants <12 months 
reported 11.3% of the participants as sensitised to one of the 10 foods tested. The overall 
prevalence of challenge-proven FA was 3.8% with 2.5% having egg allergy and 1.3% cow’s 
milk allergy (11).  
An unselected population of 1604 infants in Chongqing, Zhuhai and Hangzhou aged 
between 0-2 years reported the prevalence of challenge-proven FA from the three cities 
to be 7.3%, 5.8% and 5.5% respectively (64). 




5.2 Taiwan and Thailand 
A Taiwanese survey on 30018 participants estimated the overall self-reported and expert-
screened (convincing history ± SPT/lgE/OFC) FA prevalence to be 7.0% and 3.4% in children 
<3 years (13). A prevalence rate of 6.3% based on self-reported FA and a challenge-proven 
rate of 0.5% were observed in a Thai survey involving 656 children (3 months-6 years) in 
Bangkok (65). 
5.3 Israel 
An unselected population of 9070 Israeli infants aged 0-2 years showed a 1.2% prevalence 
of clinically relevant lgE mediated FA. 61.5% infants were allergic to 1 food, 27% to 2 foods, 
and 11.5% to ≥ 3 foods (19). 
5.4 Food allergy in Africa 
Africa is characterised by a scarcity in epidemiological data for FA in the paediatric 
population. It is debatable or whether this is due to lack of research or the prevalence of 
FAs is really low (76). The accepted notion is that FA disorders are not a major public 
health issue, however, there is increasing acknowledgement that the prevalence of FA is 
on the increase (77). 
5.4.1 Zimbabwe 
In Harare, the 5 year (1997-2002) period prevalence of FA was 10% in a cohort of 14 000 
patients of all ages referred to the specialist allergy clinic (67). A sub-study on this cohort 
on 50 allergic patients showed FS rates based on specific lg-E antibodies to be 24%, 24%, 
22%, 22%, 18% for apple, tomato, soy, crab and peanut respectively (66).  
5.4.2 Ghana 
In a questionnaire based survey of 1431 school children (5-16 years), 11% reported adverse 
food reactions. Overall, 5% had a positive SPT with FS rates of 2% each for peanuts and 
pineapple. 0.8% had a history of an adverse food reaction and a positive SPT (68). 





In Gaborone, atopic patients (3 months-51 years) with a suggestive allergic history or 
moderate to severe AD were screened by clinicians for FA and had SPTs performed. 
Overall, 14.5% were sensitised and the FS rates were; 9% egg, 8% peanut and 1.6% cow’s 
milk. The patients with FA were children aged 11 months–8 years, with AD and their 
positive tests for egg and milk were above the 95 % PPVs for sIgE (69). 
5.4.4 South Africa 
The largest body of literature on FA in Africa comes from South Africa. Most studies are 
from selected populations and one is from an unselected population. In an unselected 
Cape Town sample of 212 Xhosa high school students, 5.4% had positive SPTs. The 
common allergens were; egg 3.3%, peanut 1.9% and milk 1.9%, however all participants 
tolerated the foods (70). A case-control study in Pretoria checking for co-morbid 
conditions in 100 asthmatic children showed the following FS rates; 9% peanut, 7% egg, 4% 
wheat, 4% fish and 3% milk (71). 
In Bloemfontein, Mercer et al assessed 771 patients (3 months-15 years) with hayfever for 
sensitisation by performing SPT and sIgE to certain foods. In 275 children, sensitisation by 
SPT was mainly towards milk 30.6%, wheat 30.6% and fish 26.2%. sIgE (ImmunoCAP) on 
761 patients showed positivity to wheat 24.4%, milk 9.9% and fish 5.9% (72). 
Another Cape Town study recruited 400 allergic children and reported an overall 
sensitisation rate using immunoCAP to be 13% with most sensitisation occurring in 
eczematous children. The implicated foods were; peanut 35%, egg white 30%, milk 17%, 
fish 4%, tree nuts 3% and potato 3% (73). 
In Johannesburg, 468 Caucasian asthmatics were evaluated and had SPT performed on 
12% of the patients >4 years. The levels of sensitisation were; 30.4% wheat, 18.2% peanut, 
15.1% fish, 12.7% soy, 6.9% egg and 5.4% milk (74). 
 




A heterogeneous group of 161 South African infants with AD aged 12-24 months were 
analysed as a part of the multi-centre Early Prevention of Asthma in Atopic Children 
(EPAACTM). The sensitisation pattern using immunoCAP showed slightly higher levels of 
sensitisation in South African estimates compared to the global estimates; 47.1% vs 41.9% 
egg, 28.4% vs 27.4 cow’s milk and 26.8% vs 24.4% peanut respectively (75). 
Recent findings from a study involving children with AD at the Red Cross War Memorial 
Children’s Hospital (RCWMCH) showed relatively high FS and challenge-proven Ig-E 
mediated FA rates in the mixed race and black African participants. Overall, 66% were 
sensitised, 42% had confirmed allergies to at least one of the foods and 12% had multiple 
FAs. Amongst the black African participants, 17% were challenge positive for peanut 
allergy (21). 
6. Risk factors for food allergy 
The natural course of FA is a dynamic process that is different with each food allergen. 
The reason why some individuals are allergic to particular foods while others are not is 
unknown. But like other diseases the development of FA is multifactorial  and can be 
caused by one or a clustering of the following risk factors: genetic susceptibility, 
environmental, or nutritional factors (5). Numerous prenatal and postnatal factors fall 
under these overarching themes (Figure 2.3). 
The focus for possible interventions includes prenatal and postnatal environmental 
influences (78) and there is belief that environmental factors are the main drivers of the 
increasing FA prevalence globally (79). 
6.1 Prenatal factors 
6.1.1 Family allergic disposition 
Generally, the presence of concomitant allergy or allergic sensitisation in the individuals, 
the parents or the siblings is believed to be strongly associated with the risk of 
developing FA (78,80,81). 
 




FIGURE 2.3: Risk factors for food allergy.  
Adapted from Hidalgo-Castro et al. (82)  and Ezendam et al. (83). 
 
 
6.1.2 Age and Sex 
It is believed that children <3 years have the lifetime peak prevalence of FA (21) with most 
sensitisation/allergy happening in the first year of life (84,85). Amongst children, being 
male is believed to be associated with an increased FA risk (80,86), however other 
studies reported no association (87). 
 






























































6.1.3 Delivery Mode 
It is hypothesised that caesarean delivered infants are not exposed to commensal vaginal 
microflora leading to gut colonisation by bacteria that further skew the T-helper 2 
immune response increasing FA risk (88). Studies suggesting an increased FA risk (89,90) 
in caesarean delivered infants and no such association (91) have been reported. 
6.2 Postnatal factors 
6.2.1 Maternal practices 
In a Swedish study, children whose parents cleaned pacifiers by sucking them were less 
likely to have asthma, eczema and FS (OR: 0.37) at 18 months than children whose 
parents did not (92). A Germany study reported an increased risk (OR: 2.3) of 
sensitisation in infants whose mothers smoked up to the end of pregnancy and 
continued after birth compared to infants whose parents did not (93). 
6.2.2 Breastfeeding 
Breastfeeding exclusively and delaying solid food introduction for the first 4 months of 
life have been reported to decrease FA risk (94,95). However, there are reports of no 
difference in FS rates between children exclusively breastfed for at least 4 months and 
those formula-fed (96).  
6.2.3 Timing of complementary feeding 
Previously, feeding guidelines for prevention of FA recommended the delay of solid 
foods, however the manipulation of the diet during pregnancy and early infancy remains 
highly controversial (97,98). It has more recently been proposed that there is a window 
of opportunity in timing of oral food exposure to induce tolerance (Figure 2.4) (99,100). 
The type (form or processing) of food first introduced may also be of importance. 
The studies of good quality found no benefit of delaying the introduction of solid foods 
for longer than 4 months in high risk populations (101) and in normal risk populations 
(102). Decrease in FA risk was actually observed in an unselected cohort that introduced 
solids earlier than 4 months (103).  




Figure 2.4: Possible window of tolerance for introduction of complementary foods (99). 
↑RISK WINDOW    ↑RISK                                             RESOLUTION 
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6.2.4 Maternal and infant food avoidance 
There is increasing global acceptance that introducing food during the critical window of 
immune tolerance development, could possibly prevent allergy development (104,105). A 
trial reported a higher prevalence of atopy at 8 years in the mothers who avoided 
particular foods in the first 9-months of life while breastfeeding compared to mothers 
who did not (106). There are numerous studies underway assessing earlier introduction 
of solids as an intervention measure against FA like EAT (107) and LEAP (108). 
6.3 Dietary factors 
6.3.1 Anthroposophic lifestyles 
The keys features of this lifestyle are the restricted use of antibiotics, antipyretics, 
vaccinations and strict dietary habits (109). In a Swedish study, the FS rates based on sIgE 
levels was lower (9%) in children from anthroposophic families compared to children 
from other families (16%) (110). 
6.3.2 Pro/Prebiotics 
The addition of pre/probiotics to infant formulas is intended to modify the infants gut 
microbiota thereby reducing the risk of developing allergies. Probiotic research data 
currently is relatively inconclusive with the same formula showing different effects in 
different countries. Prebiotic data is mainly limited to company sponsored studies. The 
studies that have looked at infant pre/probiotic supplementation have either yielded 
insufficient evidence or found no evidence of benefit (111-115).  




6.3.3 Vitamin levels 
Specific vitamins have been shown to skew influence of T-cells towards the helper sub-
classes implying that vitamins may be involved in modulating allergic reactions (116). A 
German study by Weisse et al measuring Vitamin D levels in maternal and cord blood 
found a positive correlation with the infants’ risk of FA within the first 2 years of life (117). 
Contrary findings have also been observed, a cohort study found possible protective 
effects of taking vitamins before the age of 5 years (118). 
6.3.4 Partially hydrolysed infant formulas 
When breastfeeding fails or is insufficient, breast milk is replaced by modified cow milk 
formulas. Certain partially and extensively hydrolysed formulas have been shown to be 
effective in the prevention of allergic diseases in high risk individuals (83,119). In the 
German Infant Nutritional Intervention study (GINI) and its follow-up at 6 years, the 
hydrolysed formulas had significant lower incidences of allergic disease compared to cow 
milk formula. The estimates were; extensively hydrolysed whey-based (OR: 0.86 & 0.90), 
partially hydrolysed whey-based (OR: 0.65 & 0.82) and extensively hydrolysed casein 
based (OR: 0.51 & 0.80) respectively (120,121). 
6.3.5 Fish oil supplements 
Increasing n-6 polyunsaturated fatty acid (PUFA) intake (implying reduced n-3 fatty acids 
consumption) may be one of the triggering factors for the increasing sensitisation to 
food allergens (122). A systematic review looking at n-3 PUFA supplementation during 
pregnancy/lactation found significant protective effects against egg sensitisation at 12 
months (OR:0.33).(123). Conversely, findings of no benefit from fish oil supplementation 
have also been reported (124).  
 




6.4 Demographic factors 
6.4.1 Race and ethnicity 
Findings seem to suggest that race influences sensitisation and/or FA rates. Black 
children were more likely to be sensitised to foods (OR: 2.34) and were sensitised to 
more foods (OR: 3.76) compared to Hispanics based on self-identified race (125). Studies 
have also shown higher FS rates in black participants and it is suggested that there could 
be a gene or other environmental factors making black children more sensitised or 
sensitisation is just more prevalent in the ethnic group (126,127). 
6.4.2 Socio-economic factors 
A higher socio-economic status (SES) and living in affluent societies are believed to 
increase FA risk. A survey in USA showed significantly decreased odds of FA in those of a 
lower SES (<$50000 vs ≥$50000: OR: 0.5) (24) Contrary findings of a higher SES being 
protective (OR: 0.65) against sensitisation have also been reported (128). 
Another survey in USA reported that children in families that had someone with > high 
school education were more likely (OR: 1.27) to have FA as reported by a health 
professional compared to those with < high school education (129). 
6.4.3 Migrant populations 
Rapid urbanisation, the adoption of westernised lifestyles and the nutritional transition 
are believed to be associated with increased FA rates. The Cape Town, South Africa 
population grew by 1.4% in the past decade and the majority of immigration occurred 
from rural Black Africans from the Eastern Cape settling in urban informal settlements 
(130). This population is exposed to a low socio-economic environment that may contain 
many of the factors that affect foetal programming and skew subjects towards allergy, 
including a high prevalence of cigarette smoke exposure, changes in viral, bacterial and 
parasitic exposures, changes in allergen and pollutant profiles and dietary modifications. 
These changes in the environment may affect gene expression with the loss of protective 
factors and acquisition of risk factors leading to manifestation of allergies (21).   




6.4.4 Childhood obesity 
Obesity may be a contributor to the increasing prevalence of FA in children. Systemic 
inflammation might play a role in the development of allergic disease (131). In the USA 
NHANES of 2005-2006, significantly increased rates of FS were observed in obese 
children compared to normal weight children (aOR: 1.59) (132). 
6.5 Host microbiome 
6.5.1 Family size and day-care attendance 
With increasing household size/day-care attendance it is believed that the rates of FA 
decrease because of high exposure to infections. When screened for peanut, sesame and 
egg allergy, infants in the AHNS demonstrated a significant 30% reduction in challenge-
proven FA associated with having siblings (133).  
Similarly, significantly reduced likelihoods of challenge-proven egg, sesame and peanut 
allergy were observed amongst children attending childcare in the first 6 months of life 
(aOR:0.5) when compared with those cared for at home (133). 
6.5.2 Pet exposure and farming environment 
High microbial exposure from pet ownership or a farming environment, either through 
contact with farm animals or consumption of unpasteurised milk, promotes the 
development of the non-allergic phenotype (134) The AHNS demonstrated a significantly 
reduced risk of challenge-proven egg, sesame and peanut allergy amongst infants living 
with a dog during the first year of life (aOR:0.6) (133). 
6.5.3 Early life infections and antibiotic use 
Infections in early life are thought to reduce FA risk later in life while on the other hand 
taking antibiotics increases FA risk via increased risk of eczema (135,136). German adults 
who self-reported infection with any disease in childhood had a significantly reduced risk 
of sensitisation (aOR: 0.8) compared to those who did not report (137). Conversely, a 
systematic review on antibiotic use in the first year of life and FA risk found no 
association (79). 




6.5.4 Childhood vaccinations 
It is speculated that vaccinations increase FA risk either because of modulation of the 
immune system or because certain immunisations contain proteins such as gelatin, 
casein (milk), eggs and yeast (138,139). In a survey of school children, parent-reported 
rubella infection amongst unvaccinated children appeared to be protective against FA 
(aOR: 0.2) (140). However, a systematic review found no protective benefit of the BCG 
vaccination against FA (141). 
6.5.5 Gut microbiota 
The infantile gut flora shapes the immune response and is perceived to influence allergic 
outcomes (142,143). Differences in the gut microbial composition between infants who 
later developed or those who did not develop allergy were demonstrable before any 
clinical manifestations of atopy in the first 2 years of life in the Estonian and Swedish 
cohorts (143). 
6.5.6 Season  
Studies suggest that FA is more common in infants born in winter or autumn. The cause 
could be the UV-B exposure and subsequent lower vitamin-D levels during critical periods 
of immune development. In Boston, increased odds (1.53) of FA in children <5 years born 
in the winter were reported (15,144,145). 




7 Gaps in knowledge 
FA has grown to be an important public health problem in western countries affecting 
millions of people. The challenges of an increasing FA prevalence have led to large 
epidemiological studies in unselected populations such as EuroPrevall in Europe (146) 
and the AHNS (147). However, studies undertaken locally have been mostly in selected 
populations (e.g. eczematous and AD infants) and only one study in unselected black 
African teenagers. 
It was widely accepted that FA is rare in South African children, particularly the black 
South Africans. This perception is changing since higher than anticipated FS rates are 
being observed in this ethnic group in studies from selected populations (70). Migrant 
populations of indigenous black Africans moving to urban areas and assuming 
westernised diets may be influencing the increase in FA prevalence rates (21). On this 
premise this study aims to determine the prevalence of FS and challenge-proven Ig-E 
mediated FA in an un-selected population of children aged 12-36 months in Cape Town. 
The study is the first phase of the South African FS and FA study (SAFFA) that seeks to 
examine inter-ethnic differences in sensitisation and challenge-proven allergy in the Cape 
Town cohort and rural Eastern Cape cohort.  
Determining the prevalence in a random urban sample is important towards ascertaining 
the possible public health burden of Ig-E mediated FAs. Findings may be used to 
influence advocacy and policy regarding health service provision for both children and 
their families (6). Subsequent study findings will compare the 95% PPVs for a positive 
food challenge using SPTs in South Africa compared to international cohorts and will 
attempt to describe the prevalence of modifiable and non-modifiable risk factors. 
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Abstract  29 
Basera W 30 
A cross-sectional study of Ig-E mediated food sensitisation and food allergy in an 31 
unselected population of South African children aged 12-36 months. 32 
Curr Allergy Clin Immunol 33 
Background: The recent increase in food allergy (FA) prevalence (the ‘second wave’ of 34 
allergy epidemic) has been inadequately studied in developing countries. In South Africa, 35 
the prevalence of Ig-E mediated FA and food sensitisation (FS) is unknown. The study 36 
aimed to determine the point-prevalence of FS and Ig-E mediated FA in an unselected 37 
population of South African children of various ethnic backgrounds. 38 
Methodology: A sampling frame was used to randomly select children aged 12-36 months 39 
attending crèche in the Cape Town Metropolis. Parents of the children completed a 40 
questionnaire and their children underwent skin prick testing to 7 foods, viz cow’s milk, 41 
egg, fish, hazelnut, peanut, soya and wheat (flour). Those with SPT≥1mm > the negative 42 
control and not clearly tolerant (on history) to 1 or more foods underwent oral food 43 
challenges (OFCs). Parents who chose not to participate completed a non-participant 44 
questionnaire. 45 
Results: Study design was acceptable and feasible in this setting with a good response 46 
rate of 66% (141/213), participation rate of 92% (129/141) and completion rate of 94% 47 
(121/129) with 213 participants in the sampling frame. The completed participant sample 48 
consisted of 39% black African, 20% Caucasian and 41% mixed race participants, with a 49 
median age 26 months (IQR 22; 31). The prevalence of SPT≥1mm to any food was 16%, 50 
SPT≥3mm 12%, SPT≥7mm 4% and OFC confirmed Ig-E mediated FA was 1.7%. Challenge-51 
proven Ig-E mediated egg allergy prevalence was 1.7% and peanut allergy 0.8%. Black 52 
African participants had higher FS rates when compared to Caucasian and mixed race 53 
participants but the trends did not reach statistical significance.   54 
Conclusion:  This study was acceptable and feasible in this population. The prevalence of 55 
FS is high in this sample and there are ethnic differences that require further 56 
investigation.  57 




Key Words: Africa, children, cow’s milk, egg, food allergy, food sensitisation, Ig-E 58 
mediated, Incremental food challenge, peanut, skin prick testing 59 
Request for offprints: Wisdom Basera. Department of Paediatrics and Child Health, Red 60 
Cross War Memorial Children’s Hospital, University of Cape Town, Klipfontein Road, Cape 61 
Town 7700 South Africa. wisdombasera@gmail.com 62 
Key Messages 63 
 This is the first South African food allergy study in an unselected population. 64 
 The study was acceptable and feasible in this population assumed to be 65 
representative of the Cape Town population. 66 
 The prevalence of food sensitisation is high (16%) in a sample of children aged 12-36 67 
months. 68 
 Most sensitisation in decreasing frequency was towards egg, peanut and soya. 69 
 The prevalence of challenge-proven Ig-E mediated food allergy was 1.7% for raw egg 70 
and 0.8% for peanut butter. 71 
 Black African participants are more likely to be sensitised and allergic compared to 72 
Caucasian and mixed race participants.  73 
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1 Introduction 88 
Epidemiological data on FA is predominantly situated in the developed world (1). 89 
Evidence suggests that there may be a ‘second wave’ of the allergy epidemic with FAs 90 
increasing in a similar fashion, albeit a few decades later, to other allergic diseases 91 
(allergic rhinitis, eczema and asthma) (2). There is very little data on FS and challenge-92 
proven Ig-E mediated FA in unselected population based studies in the developing world. 93 
The potential increase in FAs impacts at multiple levels, including the food industry, 94 
health care professionals and the wellbeing of nations at large. However, prevalence 95 
estimates vary widely and studies have a high degree of heterogeneity because of small 96 
sample size studies, selection bias, different response rates, differential report of FA, 97 
inconsistent FA definitions and variations in data analysis (3). 98 
Many studies base FA on self-reports and few have utilised objective measures to 99 
diagnose FA (4-6). This leads to an overestimation of FA with estimates varying from 20-100 
35% (7-9). However, recent findings in children under-five years report the prevalence to 101 
be 1-2% to over 10% based on OFC confirmed Ig-E mediated FA (10,11). 102 
In South Africa, research shows an increase in respiratory allergies similar to that in the 103 
westernised countries but following it by several years (12). In South Africa there are 104 
differences in prevalence of respiratory allergy, eczema and aeroallergen sensitisation 105 
according to ethnicity and socio-economic class which may reflect diverse environmental 106 
exposures, genetic influences or epigenetic phenomena (13). Studies performed in Africa 107 
have reported FS rates or allergies based on questionnaire surveys mostly in selected 108 
populations (14,15). There is no data on the point-prevalence of FS and challenge-proven 109 
Ig-E mediated FA in unselected African populations. 110 
It is believed that FA is rare in South Africa especially in the black African population 111 
however, the rise in respiratory allergy in rural and the black African population thought 112 
to be associated with changes in living environment (urbanisation) may precede a similar 113 
increase in FS and Ig-E mediated FA. There is therefore a need to determine prevalence, 114 
particularly at the age that FAs are likely to peak and compare the local FA burden to 115 
global estimates using similar objective measures (16).  116 




The aim of the study was to determine the prevalence of FS and challenge-proven Ig-E 117 
mediated FA in an unselected sample of 12-36 months children in Cape Town, South 118 
Africa. This study is the first phase of the broader SAFFA (South African FS and FA) study 119 
which aims to increase understanding on the prevalence, the possible risk factors and 120 
diagnosis of common Ig-E mediated FAs in the local context. 121 
2 Methodology 122 
2.1 Design and setting 123 
This was a cross-sectional study from February 2013-October 2013 conducted in crèches in 124 
the Cape Town Metropolis. Participants were recruited from crèches using an allergy 125 
questionnaire and SPTs, and if they qualified, were invited to the Red Cross Hospital 126 
Paediatric Allergy Clinic (RCHPAC) for further investigations.  127 
2.2 Population and sampling frame 128 
From an online database of Cape Town registered crèches maintained by the provincial 129 
Department of Social Development (DSD) a random sequence of numbers was 130 
generated using Microsoft excel and we selected 20 crèches. Once a crèche agreed to 131 
participate from this list we approached all eligible children (213 children) between the 132 
ages 12-36 months to participate and we stopped (at 8 crèches) once we had achieved 133 
the sufficient study numbers after considering all the non-completion. 134 
Selection of participants was based on equal probability of selection method, were 135 
eligible children (source population) from different ethnic backgrounds attending 136 
crèches in Cape Town had an equal chance of being part of the study population. The 137 
study population was therefore a random sample that was assumed to be representative 138 
of children who are 12-36 months in the Cape Town urban population. 139 
2.3 Recruitment and assessment 140 
All participants were assessed by the team with an allergy questionnaire and a general 141 
physical exam for signs of eczema, hayfever and asthma. Non-participants completed a 142 
non-participant questionnaire which had questions on demographics and allergy 143 
information to assess for participant selection bias. 144 




2.3.1 Skin prick testing 145 
SPTs were done using standardised solutions from ALK Abelo (Thermo FisherTM) and ALK 146 
lancets, to egg white extract, peanut, cow’s milk, wheat (flour), soy, hazelnut, fish (cod), 147 
positive (10mg/mL histamine) and negative (saline) controls. In addition, modified SPTs 148 
for egg, milk and peanut were performed using raw egg white, fresh cow’s milk and 149 
fresh peanut butter. The skin on the forearm was pricked through a drop of the extract. 150 
SPT results were read at 15 minutes and recorded as average wheal diameter size in 151 
millimetres.  152 
2.3.2 Indications for oral food challenges 153 
All participants with any sensitisation (SPT≥1mm > the negative control) to the foods 154 
tested, but for whom tolerance was not clearly reported on clinical history were eligible 155 
for a food challenge unless there was a history of a recent anaphylactic reaction (<6 156 
months for peanut and <2 months for all other allergens) with high SPTs greater than 157 
previously published 95% PPVs (>24 months old: milk ≥8mm, egg ≥7mm & peanut ≥8mm 158 
and <24 months old milk ≥6mm, egg ≥5mm & peanut ≥4mm) (17).  159 
 160 
Participants who recorded any SPT≥1mm > the negative control who were not tolerating 161 
the normal age appropriate serving of the food or not yet exposed to that food were 162 
invited for an OFC.  Those with a SPT≥1mm but were currently tolerating the food with no 163 
history of any reaction to that food were not eligible for an OFC. 164 
2.3.3 Oral food challenges 165 
Challenges were performed as open incremental oral challenges at the RCHPAC using a 166 
standardised protocol adapted from the Australian HealthNuts study (AHNS). In 167 
completing an OFC, the general target dose recommendations are 8-10g protein for dry 168 
foods, 16-20g for meats and 100 ml for wet food. OFCs were initiated with 0.1-1% of the 169 
total challenge food however the European Academy of Allergy and Clinical Immunology 170 
(EAACI) proposes lower initial doses for OFCs to the following common food allergens: 171 
peanut 0.1mg, milk 0.1ml, egg 1mg, fish (cod) 5mg, wheat 100mg, soy 1mg, shrimp 5mg 172 
and hazelnut 0.1mg.  173 
 174 




Following the initial dose, the challenge food was then given in gradually increments 175 
every 15 minutes (18,19). The doses and the incremental times for the different challenge 176 
foods are documented in Appendix 5. Food challenges were stopped if they met pre-set 177 
standardised positive criteria (Appendix 5) (20) and the participant was treated 178 
according to protocol. Participants were observed for a minimum of 2 hours after a 179 
negative challenge and 2-4 hours after a positive challenge. 180 
 181 
After a negative challenge parents were encouraged to include the food in the diet 182 
regularly and to report any unforeseen reactions on subsequent consumption. We 183 
contacted the participant’s family via telephone 48-72 hours after the challenge to 184 
enquire about delayed symptoms.  185 
2.4 Definitions of sensitisation and allergy 186 
Any food (Low level) food sensitisation – 1 or more SPT with a wheal size ≥1mm > the 187 
negative control. 188 
Moderate level food sensitisation – 1 or more SPT with a wheal size ≥3mm > the negative 189 
control. 190 
High level food sensitisation – 1 or more SPT with a wheal size ≥7mm > the negative 191 
control. 192 
Ig-E mediated FA – a positive SPT and a positive food challenge or history of anaphylactic 193 
reaction with high SPT greater than the previously published 95% PPV. 194 
2.5 Ethics 195 
This study was approved by the University of Cape Town’s Faculty of Health Sciences 196 
Human Research Ethics Committee (reference number: HREC REF: 497/2013) (Appendix 197 
1). Informed consent was obtained from the parent/guardian for participation and food 198 
challenges (Appendix 2). 199 




2.6 Data entry and Statistical analysis 200 
The data was entered into a Microsoft Access database by the investigators and cleaned 201 
using pivot tables before being exported to STATA version 11.1 (Stata Corp. College 202 
Station Texas) for analysis. Statistical tests were done according to whether the variable 203 
was continuous or categorical. Since most of our data was categorical the Chi-square 204 
test/Fisher’s exact and the Z-test were used to test for statistical difference between 205 
variables and proportions respectively. A p-value of <0.05 was considered statistically 206 
significant. 207 
3 Results 208 
From a total of 213 eligible children the response rate was 66% (141/213). We had a high 209 
participation rate of 92% (129/141) and 9% (12/141) completed the non-participant 210 
questionnaire. Of those who participated, the completion rate was 94% (121/129) and 211 
those that did not complete the SPTs because of time constraints of the caregiver (8/129) 212 
were considered as non-participants. 213 
 214 
The competed study population consisted of 121 participants with a median age of 26 215 
months (IQR 22; 31 months). The proportion of males, 62/121 (51%; 95% CI: 42-60) and 216 
females, 59/121 (49%; 95% CI: 40-58) were similar (p=0.7). There was no significant 217 
difference between the participants and the non-participants regarding history of a first-218 
degree relative (i.e. mother, father and siblings) with asthma (28/121 vs. 5/20: p=0.86), 219 
hayfever (68/121 vs. 8/20: p=0.18), eczema (32/121 vs. 3/20: p=0.27) and FA (8/121 vs. 1/20: 220 
p=0.78). 221 
 222 
The study comprised of participants from different parts of Cape Town with varying 223 
ethnicity. The proportion of black African participants was 47/121 (39%), mixed race 50/121 224 
(41%) and Caucasian 24/121 (20%). The proportion of Caucasian participants in the study 225 
sample was statistically different from the Caucasian 0-4 year old population in the most 226 
recent Cape Town census (33) of 2011 (20% vs. 8%: p=<0.0001 respectively). The 227 
proportion of black African (39% vs. 46%: p=0.10) and mixed race (41% vs. 45%: p=0.37) 228 
participants were not statistically different. 229 




3.1 Food sensitisation prevalence 230 
Nineteen participants were sensitised to one or more foods, and 102 were negative to all 231 
foods. Table 3.1 shows the prevalence of FS amongst the participants in categories of 232 
degree of sensitisation viz, SPT≥1mm, ≥3mm and ≥7mm. Overall, 16%, 12% and 4% had a 233 
SPT≥1mm, ≥3mm and ≥7mm respectively to 1 or more of the 7 foods tested. One 234 
participant had a high level of FS with SPT≥7mm to more than 1 food, however they are 235 
yet to be challenged to the 4 foods. Of the whole group, 7/121 (6%) were polysensitised 236 
with 5/121 (4%) sensitised to 2 foods and 1/121 (1%) sensitised to 3 and 4 foods each. Of 237 
those sensitised, 12/19 (63%) were tolerant to the foods on history and 7/19 (37%) 238 
underwent OFCs. 239 
3.2 Spectrum of food sensitisation  240 
SPT≥1mm was detectable in decreasing frequency to egg, peanut, soya, wheat, cow’s 241 
milk, fish and hazelnut. SPT≥3mm was detectable in decreasing frequency to egg, 242 
peanut, fresh cow’s milk, soya and hazelnut. Only three foods; fresh hen’s egg, fresh 243 
peanut and hazelnut were detectable at SPT≥7mm in decreasing frequency (Table 3.1).  244 
3.3 Perceived food allergy 245 
The rate of perceived FA was 12% as 14/121 participants reported having had a prior 246 
reaction to 1 of the foods. There was no significant difference between the rate of 247 
perceived FA in participants and non-participants (14/121 vs. 3/20: p=0.66). 5/121 (4%) 248 
participants reported having an itchy rash, diarrhoea and flushing towards cow’s milk. 249 
4/121 (3%) and 3/121 (3%) participants reported having predominantly an itchy rash towards 250 
fish and egg respectively. Lastly, 1/121 (1%) and 1/121 (1%) participants reported vomiting 251 
and diarrhoea towards soya and wheat. No reactions conformed to the World Allergy 252 
Organisation definition of anaphylaxis (21). For most of the reported reactions, the 253 
participants also reported that a doctor confirmed the diagnosis (10/14, 71%).  254 
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POSITIVE OFC (N) IG-E MEDIATED FOOD 
ALLERGY PREVALENCE 
 ANY SENSITISATION (≥1 MM) 
         N      %        95% CI 
≥3MM  
             N      %       95% CI 
≥7MM  
               N    %      95% CI 
 (%)  95% CI 
OVERALL  19 (16) 10-23 15 (12) 7-20 5 (4) 1-9 2 2    0-6 
EGG WHITE 13 (11)  6-18 7 (6)  2-12 0 -  
FRESH HEN’S EGG 14 (12)  7-19 12 (10)  5-17 5 (4)  1-9 2 2    0-6 
PEANUT 4 (3)  1-8 4 (3)  1-8 1 (1) 0-5 -  
FRESH PEANUT 4 (3)  1-8 4 (3)  1-8 2 (2)  0-6 1 1    0-5 
COW’S MILK 1 (1) 0-5 0 0 -  
FRESH COW’S 
MILK 
1 (1) 0-5 1 (1) 0-5 0 0  
SOYA 3 (3)  1-7 1 (1) 0-5 0 0  
WHEAT 2 (2)  0-6 0 0 -  
FISH 1 (1) 0-5 0 0 -  
HAZELNUT 1 (1) 0-5 1 (1) 0-5 1 (1) 0-5 -  
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3.4 Prevalence of Ig-E mediated food allergy 268 
All the participants save for one who were sensitised (7/19) and either not tolerant or 269 
who never knowingly ingested the food had an OFC. Challenge-proven Ig-E mediated FA 270 
to raw egg was present in 2/121 (1.7%; 95% CI: 0.2-5.8) and peanut butter in 1/121 (0.8%; 95% 271 
CI: 0.02-4.5) of the participants. Challenge-proven Ig-E mediated FA by sex category was 272 
1.7% (2/121) for males and 0% (0/121) for females. No participants were classified food 273 
allergic based on recent severe reactions with SPT greater that previously described 95% 274 
PPVs (17).  275 
3.5 Food sensitisation and ethnicity 276 
Black African participants exhibited higher rates of sensitisation compared to mixed race 277 
and Caucasian participants. This was shown for low level, medium level and high level 278 
sensitisation to any food. Similar higher prevalence in black African participants was 279 
shown for sensitisation to egg and peanut. However, these differences in sensitisation 280 
between the ethnic groups did not reach statistical significance (Table 3.2). Overall, a 281 
higher proportion of black African participants had a cumulative SPT wheal size ≥1mm 282 
when compared to other ethnic groups (Figure 3.1). There was no significant difference 283 
between the median cumulative SPT sizes of the ethnic groups (Kruskal wallis: p=0.15). 284 
Upon analysing for inter-ethnic group differences, there was no difference between 285 
Caucasian and mixed race participants (Mann Whitney: p=0.72). Differences between 286 
black African vs. Caucasian and mixed race participants were observed but were not 287 
statistically significant (Mann Whitney: p=0.27 and 0.07 respectively). 288 

































Cumulative SPT wheal size 
Participant cumulative wheal size by ethnicity  
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Table 3.2: Sensitisation patterns using SPT categories and ethnicity 291 
 292 
† Difference non-significant by Chi-square 293 
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3.6 Sex category and prevalence of food sensitisation  300 
A greater proportion of sensitised participants was male (14/62, 23%) than female (5/59, 301 
8.5%) and the difference was statistically significant using the Pearson’s Chi-square test 302 
(p=0.03).  303 
3.7 Concomitant allergy and prevalence of sensitisation 304 
69/121 (57%) participants self-reported any one or more of the allergic conditions. 18/121 305 
(15%), 44/121 (36%) and 40/121 (33%) reported any asthma, any hayfever and any eczema 306 
respectively. There was no significant difference between participants and non-307 
participants regarding their self-report of asthma (18/121 vs. 6/20: p=0.10), hayfever 308 
(44/121 vs. 7/20: p=0.91) and eczema (40/121 vs. 4/20: p=0.24).  309 
 310 
From those with SPT≥1mm, 15/19 had a co-morbid allergy diagnosis based on self-report, 311 
10/19 by a clinical confirmed diagnosis while 4/19 had no co-morbid condition. There was a 312 
significant difference in the rates of co-morbid allergic conditions regardless of the mode 313 
of diagnosis between those with SPT≥1mm and those not sensitised. Higher levels of 314 
sensitisation were observed in those with co-morbid allergies based on self-report 315 
compared to those with a clinically confirmed diagnosis. Participants with co-morbid 316 
allergy based on either diagnosis had a higher proportion of participants with increasing 317 
degrees of sensitisation compared to those without co-morbid allergies. However, not all 318 
the differences reached statistical significance (Table 3.3). 319 
3.8 Sensitisation pattern by SPT levels and tertile age groups 320 
A higher proportion of participants in the youngest tertile were sensitised compared to 321 
those in the older age tertiles. However, the decrease in sensitisation rate with increasing 322 
age did not reach statistical significance (Table 3.4). 323 
Table 3.4: Sensitisation pattern by SPT category and tertile age group 324 
 12-24 MONTHS 25-29 MONTHS 30-36 MONTHS P VALUE † 
SPT≥1MM (19) 9 (47%)  5 (26%) 5 (26%)  0.76 
SPT≥3MM (15) 7 (47%)  5 (33%) 3 (20%)  0.74 
SPT≥7MM (5) 3 (60%)  0 2 (40%)  0.33 
 325 
† Difference between the age groups non-significant by Fisher’s exact/Chi-square tests 326 
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Table 3.3: Sensitisation pattern and method of concomitant allergy diagnosis 327 







CO-MORBID ALLERGY CATEGORIES 
DIFFERENCE BETWEEN 
CO-MORBID ALLERGY CATEGORIES AND 
NO CO-MORBID ALLERGY § 
NOT SENSITISED (102) 54 (52.9%) 19 (18.6%) 48 (47.1%) <0.0001 0.58 & <0.0001 
SPT≥1MM  (19) 15 (78.9%) 10 (52.6%) 4 (21.1%) 0.09 0.0004 & 0.04 
SPT≥3MM (15) 12 (85.7%) 7 (50%) 3 (21.4%) 0.04 0.0006 & 0.11 





0.04 0.001    
 328 
† Difference significant by 2-sided test of proportions 329 
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4 Discussion 339 
SAFFA is the first study in Africa to investigate the prevalence of FS and challenge-proven 340 
Ig-E mediated FA in an unselected sample. We randomly sampled from an unselected 341 
population of children attending crèches and the approach yielded a good overall 342 
participation rate of 66%. The study was feasible and acceptable in the target population. 343 
This is despite the significant obstacles in this setting viz inability to contact parents 344 
directly for consent, unavailability of a caregiver able to give consent and the time 345 
constraints of caregivers to complete the allergy tests. We found appreciable rates of FS 346 
with inter-ethnic differences and a considerable burden of Ig-E mediated FA in the study 347 
population. 348 
To assess for selection bias in individual study participation we administered a non-349 
participant questionnaire that was answered by a small proportion of the eligible 350 
population (12/213, 6%). Those who chose not to participate did not have time to come for 351 
SPTs. The similar prevalence history of FA and concomitant atopy in participants and non-352 
participants means that it is unlikely that selection bias has had a large effect on the 353 
allergy prevalence rates. 354 
When the ethnic distribution in our sample was compared to the most recent results of 355 
the 0-4 year’s population in the Cape Town census of 2011, it showed an over-356 
representation of the Caucasian group. This may be because the online crèche list we 357 
sampled from has more contact details for crèches in the more affluent areas than the 358 
less affluent areas thereby skewing the study population. This is possible because the 359 
crèches from higher socio-economic (SE) settings are more likely to be registered than 360 
those from lower SE settings because of the stringent requirements. As a result the 361 
source population may reflect a skewed population with less representation from the 362 
lower SE settings and furthermore the crèches accessed from these areas were more 363 
difficult to organise study logistics with.  364 
 365 
 366 
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We have demonstrated high levels of FS comparable to that of previous findings from 367 
highly selected populations in South Africa and much higher than what has been 368 
previously observed in an unselected population of older high-school children with a 369 
mean age of 17 years (22). We observed high rates of FS in the black African vs. mixed 370 
race and Caucasian participants similar to the pattern of higher rates of food and 371 
aeroallergen sensitisation observed in this sub-group in other studies (23,24). 372 
South Africa appears to have among the low levels of Ig-E mediated FA compared with 373 
data from unselected populations confirmed by food challenges in the range of 1%-10% 374 
(11). However, the rate of challenge-proven Ig-E mediated FA in our setting is similar to 375 
that reported in unselected cohorts in Thailand (1%) (25) and the Nordic countries; 376 
Denmark (2.3%) (26) and Iceland (2%) (27) (Figure 3.2).  377 
The prevalence of any sensitisation to any one or more of the common allergic foods was 378 
16%; highest for egg, peanut and soya. FA prevalence was 1.7%; highest to raw egg (1.7%) 379 
and peanut butter (0.8%). There is high likelihood that the prevalence could have been 380 
higher because the 1 participant that was not challenged had a high level of sensitisation 381 
and was not tolerating the food on clinical history. 382 
Figure 3.2: Summary of OFC proven Ig-E mediated FA from studies that have data for 383 




























Australia Norway China UK UK Denmark Iceland Thailand
South
Africa
Ig-E mediated FA Prevalence (%) 10 6.8 6.2 4 2.5 2.3 2 1 1.7
Studies reporting OFC proven Ig-E mediated food allergy in Pre-school children      
≤ 5 years 
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Associations between FA and risk factors could not be assessed because of a lack of 386 
statistical power. However we explored the effect of ethnicity, age, sex and presence of 387 
co-morbid conditions on FA. Ethnic differences in sensitisation were evident between, 388 
the black African, mixed race and Caucasian participants. Sensitisation was higher in the 389 
black African compared with the Caucasian and mixed race participants. Although our 390 
numbers are still very small, the proven-allergy rate was 1.7% in the black African, 0.8% in 391 
the Caucasian and 0% in mixed race participants.  392 
It was previously thought that Ig-E mediated FA and FS are rare in the black African 393 
population but there is a suggestion of a recent emergence of allergies in this group as 394 
reported by a recent study in a selected population (24) . This cohort appears to be 395 
sensitised to common foods implying that they may have genetic predisposition for FA. 396 
The cohort also had an appreciable prevalence of Ig-E mediated FA.  It is known that not 397 
all patients with sensitisation have food allergy, however this tendency may be 398 
accentuated in our setting. This may be because of environmental protection via 399 
unknown mechanisms of epigenetic regulation.   400 
The Black African cohort had higher rates of both sensitisation and allergy although this 401 
did not reach statistical significance.  It may be postulated that a black African cohort 402 
that migrates from rural areas adopt westernised lifestyles and acquire new risk factors.  403 
At the same time they may discard traditional lifestyles and remove of protective factors.  404 
This may have caused both sensitisation and allergy rates to increase, perhaps not to the 405 
same degree. 406 
In this study, sensitisation to any food was higher in the younger age group compared to 407 
the older age groups. This is similar to the findings from selected populations in our 408 
recent study of children with AD (24) and the EPAACTM study (30) that appears to 409 
suggest that most FS is completed by the first birthday. A greater proportion of male 410 
participants compared to female participants was sensitised and had challenged-proven 411 
Ig-E mediated FA confirming findings in literature that the male sex is associated with an 412 
increased FA risk (31,32). 413 
 414 
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The presence of concomitant allergy associated with Ig-E mediated FA is shown via a 415 
higher proportion of participants with SPT≥3mm and SPT≥7mm when compared to those 416 
with no diagnosis of concomitant allergy. With documented increases in the prevalence 417 
of other allergic conditions (allergic rhinitis, eczema and asthma) in the South African 418 
context mimicking the global trend of the first wave of allergy (12), there is potential for 419 
an increase in the complexity and severity of FA as the allergy epidemic advances.  420 
The study reflects the community prevalence of Ig-E mediated FA in South African 421 
children aged between 12-36 months. However, the risk factors influencing the 422 
prevalence and the differences between the ethnic groups could not be explored 423 
because of a lack of precision. The second phase of the study will focus of determining 424 
the inter-ethnic differences and rural-urban differences in the prevalence of FS and FA in 425 
South Africa. The study will further explore whether the 95% PPVs for a positive food 426 
challenge using SPT are the same in South African children as international cohorts, and 427 
will attempt to describe the modifiable and non-modifiable risk factors. 428 
5 Conclusion 429 
Ig-E mediated FA and FS rates in this unselected South African sample were higher than 430 
expected since they were comparable with rates from local studies in selected cohorts 431 
and were equivalent to unselected cohorts in Denmark, Iceland and Thailand. There are 432 
ethnic differences, with the black African participants having higher levels of 433 
sensitisation and proven allergy than Caucasian and Mixed race participants. Further 434 
investigations should explore the prevalence of FS and FA in both urban and rural South 435 
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2. Parent Information Sheet and Consent 
This Information Sheet has been written to help you decide if you would like you and 
your child to participate in the SAFFA Study.  Please read this Information Sheet carefully 
and feel free to ask questions to any of the staff members or contact Dr Maresa Botha on 
021 658 5779 or 0762540860. 
 
By signing the Consent Form, you indicate that you have read and understood this 
Information Sheet and that you give consent for your child to take part in the SAFFA 
Study on the terms set out in this Information Sheet. You will be given a copy of this 
Information Sheet to keep as well as a copy of the consent you’ve signed. 
 
Before you decide you need to understand why the research is being done and how you 
will be involved. Please read all the sections carefully and feel free to ask questions to 
members of staff if you wish. Your participation in the study is entirely voluntary and 
your child’s care will not be affected if you decide not to take part. 
 
Why is this study being performed? 
Studies in other parts of the world, especially in Europe and the USA, have found that 
many children have allergies to certain foods. Food allergies are very common especially 
in children between 1-3 years. In some children food allergies may cause problems such 
as an itchy rash, breathing difficulties or even collapse soon after they eat the food they 
are allergic to. This can be a medical emergency. In other children, eating the food they 
are allergic to may cause their eczema to get worse many hours to days after eating the 
food. It is important to know about such food allergies so that the child can get the right 









Previously we had thought that food allergies were not very common in the South 
African children and especially rare in black South African children. We are trying to find 
out how many South African children have food allergies, to see whether it is as common 
as in the overseas studies, or whether it is perhaps not common here, and what the 
factors are that may be associated with food allergy in this country. 
 
Why has your child been invited to take part? 
We are inviting 1200 children between 12 months and 36 months who attend crèches in 
Cape Town and Bulungula (Eastern Cape) to take part in the study. 
 
Do you have to take part?  
You are not in any way obligated to take part in our study. Taking part is entirely 
voluntary. Your child will only be entered with your permission and signed consent. Your 
child’s medical care will not be affected in any way whatever you decide to do. If you say 
yes to be part of the study and later change your mind, you can do this without any 
consequences to your child or his/her medical care. 
 
What will happen if you decide to take part? 
1. We will describe the study to you and answer any questions you may have. We wil l 
ask you to sign a consent form if you decide to take part. 
 
2. Your child will be seen by one of the study team members and you will be asked 
questions about the child’s medical history and diet. We will also ask you about any 
allergies you may know of and some questions about allergies in your family. If there 
is anything from what you tell us that makes us think that your child might have had a 
reaction to food in the past, we will ask you to come to Red Cross Children’s Hospital 
where your child will have a Skin Prick Test, some blood tests and an Oral Food 
Challenge done. We will explain these to you should it be necessary. If there is no 
concern from what you tell us about food allergies, we will do a Skin Prick Test here in 
the Clinic. If the skin prick test shows no reaction, your child will have no further test 
performed. 




3. We will examine your child to see if we can find any evidence of eczema, hay fever or 
asthma. 
 
4. You will be seen by a nurse who will do skin prick tests for 7 common foods to look 
for signs of possible allergies (egg, milk, peanut, hazelnuts, wheat, soya and fish). For 
the Skin Prick test we will put small drops of special mixtures containing food 
proteins on to the child’s arm or back, and gently scratch the skin with a sharp lancet 
and wait for 15 minutes to see if there is a reaction on the skin. Skin prick tests are not 
very painful – they feel a bit like a mosquito bite.  
 
The arm may become itchy, and if this happens we will give your child a cream to put 
on or medicine to drink (both antihistamines). Very rarely do children get more 
serious reactions like a wheeze or a more serious allergic reaction. Even though these 
reactions are extremely rare (about one in a 1000 children will have a more severe 
reaction) we are experienced to recognise any problems and will have emergency 
medicine with us to give immediately should your child have any signs of a more 
serious reaction.  After the Skin Prick test is done you will need to wait for 15 minutes 
to see what the result is. If there is any reaction it may indicate that your child is 
sensitive or maybe even allergic to that particular food. We will then arrange for your 
child to have further tests (an oral food challenge and blood and stool tests) done at 
Red Cross Children’s Hospital. 
 
5. If your child has a history or a skin prick test result that makes it likely that he/she has 
a food allergy, we will also do some blood tests. Some of these bloods are part of the 
routine care of a child with a possible food allergy. Other blood tests are for the 
purposes of our research study and will help us to look for risk factors that might 
cause food allergies.  These risk factors include genetic information.  
 
Part of our research study includes genetic analysis of the blood of some of our 
participants. This analysis will only be of factors related to allergic diseases and not of 
any other illnesses that can be investigated through genetic testing.  




Some of the bloods will be stored for future testing but once again only for research 
related to allergy diseases. The blood samples and the information they contain will 
stay the property of the University of Cape Town and will not be sold for profit and 
will only be used for research that has been approved by the Human Research Ethics 
Committee of the University of Cape Town.  
 
6. If there are any positive results for allergy tests your child may be asked to come to a 
hospital another day for a “food challenge.” A food challenge involves coming in to 
hospital for the morning, and your child will be given very small amounts of the food 
to which they had a positive allergy test. This will be given under medical supervision 
to check for a reaction. We will then give bigger and bigger amounts of the food as 
long as there is no reaction. We will explain this in detail to you if your child needs a 
food challenge.  
 
7. If we find that your child has a food allergy, we will arrange for you to see a dietician 
to give advice on avoiding the food; and we will give you a treatment plan and 
medications for an accidental allergic reaction. We will also arrange for you to be 
seen in the allergy clinic or the local hospital along with the history, results of your 
investigations and the challenge test.   
 
How much time will you have to spend on the study? 
We are hoping to perform all of the tests (questions and skin tests) on the same day over 
about ½ hour. If your child has taken antihistamine medicines in the previous few days 
we will need to arrange the skin tests for another day. 
 
If your child needs a food challenge, this will be arranged for another day and will involve 
a half day visit to the hospital. If your child has a reaction during the food challenge they 
will need to stay a few hours longer so that we can watch them carefully. Very rarely 








What about expenses and payment for the study? 
You will not be paid for taking part in the study, but if you need to make any trips to the 
hospital for the study, we will pay travel expenses of R150 per day (or actual expenses 
should they be more than this).  
  
What are the possible benefits of taking part? 
The information from this study may help to improve our understanding of food allergies 
in South African children.  It will be helpful to know if your child has food allergies so that 
we can try and avoid reactions to certain foods and refer you for follow up. It will also be 
helpful to know if your child is not allergic to foods as you can then use the food in the 
child’s diet without worrying about it. 
  
What are the possible disadvantages of taking part? 
There is a very small risk of a reaction to skin tests but these will be performed in a safe 
environment by trained individuals.  
For those having blood tests there is a chance of temporary bruising and pain where the 
blood was taken.  We will put a special local pain-numbing cream on the skin to numb 
where the needle goes in. 
 
If your child needs a food challenge, there is a risk of an allergic reaction. If there is an 
allergic reaction, it is usually mild, such as a rash. In a small proportion of children having 
a food challenge (about one in ten) there may be a more severe reaction such as 
breathing difficulties, which we will treat immediately. We will give the foods starting in 
very small amounts, and the child will be closely watched between each dose to make 
sure we recognise any reactions early on. Your child will be in the hospital setting where 
all emergency treatment is available, so it is much safer than giving the food at home.  
 
What if there is a problem?  
You may at any stage decide to withdraw from the study. This will not affect any 
treatment your child is receiving. If you have any concerns about any aspects of the 
study, please speak to the researcher who will try and help you.   




Should anything go wrong with your child during the study, you will be covered by the 
no-fault insurance offered by the University of Cape Town. 
 
Confidentiality 
Any information on your child will be kept strictly private, and if the information is 
published, we will not use any names. Thus you and your child will never be able to be 
identified by anyone except study staff. If your child has food allergy we will, however, 
refer you by name to the local health service for follow up. 
 
Who has reviewed the study? 
This study has been reviewed and approved by the University of Cape Town’s research 
ethics committee.  
 
Further information and contact details 
If you need any further information at any stage, you can contact: 
Prof Mike Levin: 021 6585111 
Dr Claudia Gray: 021 6585111 
Dr Maresa Botha: 0216585779 
























Consent Form for Participation in the Study 
 
I (name of parent or legal guardian)………………………………………………………….. 
Have been fully informed about the above study with its risks and benefits, and hereby 
permit my child (Name, Date of birth)………………………………………………….…..… 
to take part in the study. 
 
 
This consent includes the following study procedures: 
 
Asking some health-related questions 
 
YES/NO 
Examining the child 
 
YES/NO 
Skin prick tests 
 
YES/NO 
Blood and stool tests if needed 
 
YES/NO 
Dust samples from the home if needed. 
 
YES/NO 




Blood to be stored for genetic analysis related to allergy research  
YES/NO 
 




I understand that my participation is voluntary. If I refuse to permit my child to 
participate, or choose to withdraw my child at any anytime, I understand there will be no 
prejudice against me or my child by the doctors or hospital. 
 
I have been given a copy of this form. 
 










For illiterate parents only: 
 






I (study personnel name)……………………………………………………………… 
have fully explained the nature and purpose of the above described study with its risks 
and benefits. I have answered all the questions to the best of my ability. I will inform the 
participant of any changes in the procedures or the risks and benefits should they change 

















3. Participant Questionnaire 
Participant details 
Q1 Participant ID 0000/XX 
Q2 Enrolment date DD/MM/YYYY 
Q3 Study site 1 = Urban 2= Rural 
Q4 Date of birth DD/MM/YYYY 
Q5 Age at enrolment  XX months 
Q6 Sex 1= Male 2=Female 
Q7 Weight XXX kg 
Q8 Height/Length XXX cm 
 
Q9 Immunisations 
 Yes No  Yes No 
Birth 9.1 BCG    14 weeks 9.10 RV(2)   
9.2 OPV (0)    9.11 DTaPIPV/HiB(3)   
6 weeks 9.3 OPV (1)    9.12 HepB(3)   
9.4 RV (1)    9.13 PCV7 or 13 (2)   
9.5 DTaPIPV/HiB (1)    9 
months 
9.14 Measles vaccine   
9.6 HepB (1)    9.15 PCV 7 or 13 (3)   
9.7 PCV7 or 13(1)    18 
months 
9.16 DTaPIPV/HiB (4)   
10 weeks 9.8 DTaPIPV/HiB (2)    9.17 Measles Vaccine   
9.9 HepB (2)     
Q10 Vaccination Status 
1 = Complete  2 = Incomplete  
 
Q11 Paracetamol Exposure 
Q11.1 Did your child have paracetemol or medicines containing 
paracetamol in the first year of life? ( Panado, Calpol, Paramed) 
 
 
1 = Yes 
 
0 = No 
Q11.2 If Yes, How old was your child when they 








If Yes, How often did your child have paracetamol on 










More than 20 
days 
 
Q12 Childhood infections 
Has your child had any of the following childhood infections? 
  
1 = Yes 
 
0 = No 
999 = don’ t 
know 
  
1 = Yes 
 
0 = No 
999 = don’t 
know 
12.1 Measles    12.5 Glandular 
Fever 
   
12.2 Mumps  
 
  12.6 Tuberculosis    
12.3 Rubella  
 
  12.7 Hepatitis    
12.4 Chickenpox    12.8 Other (please 
specify) 
   








Did your child have any antibiotics in the 
first year of life? 
 
1 = Yes 
 
 
0 = No 
 
 
999 = Don’t know 









How many courses did your child have in 
















> 5 courses 
13.4 Did your child have any antibiotics in the 
last 2 months? 
 
1 = Yes 
 
0 = No 
 






















If Yes, at what age did they last take anti worm 
medicines? 





Has your child had regular (yearly) medicine for 
worms? 
 
 0 = No 
 
1 = Yes 
 
999 = Don’t 
know 
 
Q14 Probiotic Exposure and Amasi exposure (CHILD) 
14.1 Did this child have probiotics in food or supplements 
in the first year of life? 
 
1 = Yes 
 
0 = No 
 
999 = Don’t know 






14.3 If Yes, How often did this child have probiotics in the 









 >20 days 






Has your child ever have amasi ? 
 
0 = No 
 
1 = Yes 
 
























more than 4 
times per month 
 




Did this child’s mother have probiotics during 
pregnancy? 
 
0 = No 
 
1 = Yes 
 
999 =Don’t know 
14.9  




















Did this child’s mother regularly have amasi during 
pregnancy? 
(more than once a month) 
 





999 = Don’t 
know 
 




How was this child born? 
 
 
1 = Normal vaginal        
delivery 
 
2 = Caesarean section 
 
999 = Don’t Know 
 
Q16 Sunlight Exposure 
 
How much time does your child spend outdoors on an average day? 






00.0   hours 
 
00.0    hours 
 
999 = Don’t Know 
 
999 = Don’t Know 
 
Q17 Peanut exposure in pregnancy 
17.1 Did this child’s mother eat peanuts regularly (every 




0 = No 
 
999 = Don’t know 





0 = No 
 
999 = Don’t know 
 




Was this child ever breastfed? 
 
1 = Yes 
 
 
0 = No 
 




If Yes, up to what age was this child exclusively 
breastfed  










At what age did you completely stop 









At what age did you first introduce any other 




999 = Don’t 
know 
 
Q19 Weaning foods 
Q19.1 When did you first introduce solids 




Q19.2 Which three types of foods did you 
introduce first? (see coding chart 
















Has this child ever had non-pasteurised  
(Fresh farm) milk? 
 
1 = Yes 
 
 
0 = No 
 
999 = Don’t know 
 




Q21 Food exposure 
Foods Eaten Ever Eaten Age first eaten Still eating regularly (once 
a month or more) 
21.1 Peanut 
e.g. peanut butter, 
peanut oil, peanuts in 










































If yes to 21.1.4 
 
Please try an remember how 
many times your child ate the 
following peanut containing 
foods in the last day and week 
 








Usual amount  Total 
amount in 
grams 
Peanut butter on 
bread 
   Thin slices 21.1.4  
 Thick slices 21.1.5  
Peanut butter in 
porridge 
   Teaspoons 21.1.6  
Raw/boiled peanuts    Handfuls 21.1.7  
Roasted peanuts    Handfuls 21.1.8  
Peanuts in 
chocolate or biscuits 
   21.1.9  
Total amount of peanut consumed in the last week 21.1.10  
21.2 Other nuts 
e.g. Cashew, hazelnut, brazil 
nut, almonds, walnuts, 
pistachio, macadamia in 
chocolate and cookies or 










































1 = Yes 
21.3 Cow’s milk products 



































1 = Yes 
21.4 Cow’s milk formula 
e.g. Nan, Lactogen, 



































1 = Yes 
21.5 Soya products 
e.g. soya mince, soya sauce, 



































1 = Yes 
21.6 Soya milk products 




0 = No 
 
 















0 = No 
 
 
1 = Yes 
21.7 Hen’s egg 





































1 = Yes 
21.8 Wheat 
e.g. cereal (Wheetabix, All 
Bran, Tasty Wheat), bread 




































1 = Yes 
21.9 Fish (excluding shellfish) 
Hake, snoek, 
sardines,pilchards, tuna, 
kingklip, salmon etc and fish 
products: Fish 
paste(Redro), Worcester 














































1 = Yes 




Q22 Food Reactions 
22.1     PEANUTS 
22.1.1 Has your child ever had any of these reactions below to 
peanuts or food containing peanuts 
 
1 = yes 
 
0 = no 
22.1.2 If yes, which of the following reactions has this child had? (you can circle more than one) 
1= none 6= tight throat 11=shock/low blood pressure 
2= itchy Rash 7= wheeze 12= collapse/loss of consciousness 
3=swelling(face/lips/eyes) 8= vomiting 13 = worsening of eczema 
4= flushing 9= diarrhoea  
5= itchy mouth/throat 10= blue lips 

















22.1.5 If yes, was this reaction confirmed by a doctor?  
1 = yes 
 
0 = no 
 
22.2      OTHER NUTS 
22.2.1 Has your child ever had any of these reactions below to other 
nuts or food containing nuts other than peanuts 
 
1 = yes 
 
0 = no 
22.2.2 If yes, which of the following reactions has this child had? (you can circle more than one) 
1 = none 6 = tight throat 11 =shock/low blood pressure 
2 = itchy Rash 7 = wheeze 12 = collapse/loss of consciousness 
3 =swelling(face/lips/eyes) 8 = vomiting 13 = worsening of eczema 
4 = flushing 9 = diarrhoea  
5 = itchy mouth/throat 10 = blue lips 

















22.2.5 If yes, was this reaction confirmed by a doctor?  
1 = Yes 
 
0 = No 
 
 
22.3     COW’S MILK 
22.3.1 Has your child ever had any of these reactions below to cow’s milk or 
food containing cow’s milk 
 
1 = Yes 
 
0 = No 
22.3.2 If yes, which of the following reactions has this child had? (you can circle more than one) 
1 = none 6 = tight throat 11 = shock/low blood pressure 
2 = itchy Rash 7 = wheeze 12 = collapse/loss of consciousness 
3 =swelling(face/lips/eyes) 8 = vomiting 13 = worsening of eczema 
4 = flushing 9 = diarrhoea  
5 = itchy mouth/throat 10 = blue lips 

















22.3.5 If yes, was this reaction confirmed by a doctor?  
1 = Yes 
 
0 = No 




22.4    SOYA 
22.4.1 Has your child ever had any of these reactions below to soya 
or food containing soya 
 
1 = Yes 
 
0 = No 
22.4.2 If yes, which of the following reactions has this child had? (you can circle more than one) 
1 = none 6= tight throat 11=shock/low blood pressure 
2 = itchy Rash 7= wheeze 12= collapse/loss of consciousness 
3 =swelling(face/lips/eyes) 8= vomiting 13 = worsening of eczema 
4 = flushing 9= diarrhoea  
5 = itchy mouth/throat 10= blue lips 

















22.4.5 If yes, was this reaction confirmed by a doctor?  
1 = Yes 
 
0 = No 
 
 
22.5    HEN’S EGG 
22.5.1 Has your child ever had any of these reactions below to hen’s 
egg or food containing egg 
 
1 = Yes 
 
0 = No 
22.5.2 If yes, which of the following reactions has this child had? (you can circle more than one) 
1 = none 6 = tight throat 11 =shock/low blood pressure 
2 = itchy Rash 7 = wheeze 12 = collapse/loss of consciousness 
3 =swelling(face/lips/eyes) 8 = vomiting 13 = worsening of eczema 
4 = flushing 9 = diarrhoea  
5 = itchy mouth/throat 10= blue lips 

















22.5.5 If yes, was this reaction confirmed by a doctor?  
1 = Yes 
 
0 = No 
 
 
22.6     WHEAT 
22.6.1 Has your child ever had any of these reactions below to wheat 
or food containing wheat 
 
1 = Yes 
 
0 = No 
22.6.2 If yes, which of the following reactions has this child had? (you can circle more than one) 
1= none 6= tight throat 11=shock/low blood pressure 
2= itchy Rash 7= wheeze 12= collapse/loss of consciousness 
3=swelling(face/lips/eyes) 8= vomiting 13 = worsening of eczema 
4= flushing 9= diarrhoea  
5= itchy mouth/throat 10= blue lips 

















22.6.5 If yes, was this reaction confirmed by a doctor?  
1 = Yes 
 
0 = No 
 




22.7     FISH (excluding shellfish) 
22.7.1 Has your child ever had any of these reactions below to fish or 
food containing fish 
 
1 = Yes 
 
0 = No 
22.7.2 If yes, which of the following reactions has this child had? (you can circle more than one) 
1 = none 6 = tight throat 11 =shock/low blood pressure 
2 = itchy Rash 7 = wheeze 12 = collapse/loss of consciousness 
3 =swelling(face/lips/eyes) 8 = vomiting 13  = worsening of eczema 
4 = flushing 9 = diarrhoea  
5 = itchy mouth/throat 10 = blue lips 

















22.7.5 If yes, was this reaction confirmed by a doctor?  
1 = Yes 
 





Has your child ever had symptoms of asthma? 
(e.g. wheeze, persistent cough at night or when 
exercising, shortness of breath) 
 
 
1 = Yes 
 
 












If yes, who diagnosed the asthma? 
 
1 = Self 
 
2 = Nurse 
 
3 = Doctor 
 




Has your child ever had symptoms of hay fever 
(e.g. itchy runny eyes, itchy runny nose, blocked 
nose, frequent sneezing) without having a “cold” 
or upper respiratory tract infection? 
 
 
1 = Yes 
 
 













If yes, who diagnosed the hay fever? 
 
1 = Self 
 
2 = Nurse 
 






Has your child ever had symptoms of eczema 
(e.g. an itchy rash especially in the folds of the 
elbows, behinds the knees, in front of the 
ankles, under the buttocks or around the neck, 
ears or eyes?) 
 
 
1 = Yes 
 
 













If yes, who diagnosed the eczema? 
 
1 = Self 
 
2 = Nurse 
 










Q26 Medication use 
 
Q26.1   











Relievers (blue)  
e.g. Asthavent 
 
1 = yes 
 




spray e.g. Beclate 
 
1 = yes 
 
0 = no 
 
26.1.2 
Controllers (brown/cream)  
e.g. Budeflam 
 
1 = yes 
 




(If yes, please complete 
Q26.4 below) 
 
1 = yes 
 




(please specify below) 
 
1 = yes 
 






1 = yes 
 






1 = yes 
 
0 = no 
 
25.1.8 
Adrenalin auto injector 
or pen  
e.g. Epipen  
 
1 = yes 
 
0 = no 
 
Q26.2 
If your child is on any other oral medication (pills or 
syrups) for asthma, please specify each one. 












If your child is on antihistamines, how many days 
since they were last taken? 
1 =  
 
<2 days 
2 =  
 
2-5 days 






If your child is on any other medication for other 




Q27 Family history of allergic disease 
Does anyone in your family have allergic diseases? Please circle. 
(you can choose more than one option) 
 Family member None Asthma Hay fever Eczema Food allergy 
Q27.1 Mother 1 = none 2 = asthma 3 = hay fever 4 = eczema 5 = food allergy 
Q27.2 Father 1 = none 2 = asthma 3 = hay fever 4 = eczema 5 = food allergy 
Q27.3 Full Sibling 1 1 = none 2 = asthma 3 = hay fever 4 = eczema 5 = food allergy 
Q26.4 Full Sibling 2 1 = none 2 = asthma 3 = hay fever 4 = eczema 5 = food allergy 
Q27.5 Full Sibling 3 1 = none 2 = asthma 3 = hay fever 4 = eczema 5 = food allergy 
Q27.6 Full Sibling 4 1 = none 2 = asthma 3 = hay fever 4 = eczema 5 = food allergy 
 
Q28 Child’s Medical history 
 
Q28.1 
Does your child have any other significant medical problems? (e.g. heart or lung 
problems, kidney or liver disease, epilepsy, diabetes) 
 
1 = Yes 
 












What language do you mainly speak at home? (Please choose only one) 
1 = IsiXhosa 2 = English 3 = Afrikaans 
4 = IsiZulu 5 = Sesotho 6 = Setswana 
7 = SiSwati 8 = IsiNdebele 9=Xitsonga 




If Xhosa speaking, was this child born in Cape Town? 
 
1 = Yes 
 











If no, where was this child born? 
Province 
1 = Western Cape 
2 = Eastern Cape 
3 = Northern Cape 
4 = Free state 
5 = Gauteng 
6 = Kwazulu Natal 
7 = Mpumalanga 
8 = Limpopo 
9 = North West Province 




















Was this child’s mother born in Cape Town? 
 
0 = No 
 




If No, where was she born? 
Province (please circle) 
1 = Western Cape 
2 = Eastern Cape 
3 = Northern Cape 
4 = Free state 
5 = Gauteng 
6 = Kwazulu Natal 
7 = Mpumalanga 
8 = Limpopo 
9 = North West Province 




















Was this Child’s father born in Cape Town? 
 
0 = No 
 
1 = Yes 
 If No, where was he born? Province 
1 = Western Cape 
2 = Eastern Cape 
3 = Northern Cape 
4 = Free state 
5 = Gauteng 
6 = Kwazulu Natal 
7 = Mpumalanga 
8 = Limpopo 
9 = North West Province 










What is your child’s ethnic origin? 
(circle as appropriate) 
1 = White/Caucasian 2 = Coloured / Mixed race 
3 = Black African 4 = Asian/Indian 
5 = Other (Specify) 
 
Q31 Household information 
Q31.1 How many people live together in your house?  
Q31.2 How many children (12 years or less) that are OLDER than this child live in the 
same household? 
 










Q32 Parental Education level 
1 = None 11 = Grade 9 / Std  7 
2 = Grade R / preschool 12 = Grade 10 / Std  8 
3 = Grade 1 / SubA 13 = Grade 11 / Std 9 
4 = Grade 2 / Sub B 14 = Grade 12 / Matric 
5 = Grade 3 / Std 1 15 = Grade 9,10,11 (Std 7,8,9) & diploma 
6 = Grade 4 / Std  2  16 = Grade 12 (Std 10) & Certificate or Diploma 
7 = Grade 5 / Std  3 17 = Grade 12 (Std 10) & Degree 
8 = Grade 6 / Std  4 18 = Grade 12 (Std 10) & Degree plus Diploma 
9 = Grade 7 / Std  5 19 = Grade 12 (Std 10) & PhD 
10 = Grade 8 / Std  6  Other (Specify) : Free text 
 
 
Q33 Household income 
Q33.1 What job does this child’s mother/female guardian do?  
Q33.2 What job does this child’s father/male guardian do?  
Q33.3 How much money or income does your household receive 
every month after tax? (incl. money from work, pensions, informal 
business etc.) 








Do you own a cat or have a cat in your home? 
 
    1 = Yes 
 








0 = No 
 
Q34.3 
Does your child have regular (at least once a week) 





1 = Yes 
 
 
0 = No 
 
 




Has this child’s mother had regular (at least once a week) 
contact with farm animals (e.g. cattle, pigs, goats, sheep 
or poultry) while being pregnant with this child? 
 
 
1 = Yes 
 
 
0 = No 
 
 
999 = Don’t know 
 
 




At your house, what fuel is used for cooking? 
1 = Electricity/Gas    4 = Open fires outside the house    
2 = Paraffin Stove    5 = Other (specify) 




At your house, what fuel is used for heating? 
1 = Electricity    4 = Wood/coal   
2 =Gas    5 = Other (specify) 








Q36 Cigarette smoke exposure 
 
Q36.1 
Does this child’s mother (or female guardian) currently 
smoke cigarettes? 
 
1 = Yes    
 
0 = No   
 
3 = Don’t know 
 
36.1.1 
If YES, about how many cigarettes does the child’s 
mother (or female guardian) smoke each day? 
 
number of cigarettes: 
 
Q36.2 
Does this child’s father (or male guardian) currently 
smoke cigarettes? 
 
1 = Yes    
 
0 = No 
 
3 = Don’t know 
 
36.2.1 
If YES, about how many cigarettes does the child’s 
father (or male guardian) smoke each day?                                       
 
number of cigarettes: 
 
Q36.3 
How many people living in the house currently smoke 
cigarettes, including parents? 
 




Did this child’s mother smoke cigarettes while being 
pregnant with this child? 
 
1 = Yes    
 
0 = No    
 
3 = Don’t know 
    




4. Non-Participant Questionnaire and 
Consent 
We would be very grateful if you could take the time to complete a short survey which 
will help us to improve the quality of our study findings. These questions will be about 
your child’s diet, history of allergies and also some questions regarding your family’s 
history of allergy and where you and your child were born. 
 
This information will be anonymous and we will not keep any record of you or your 
child’s name. It will therefore not be possible to identify you or your child from the 
information you give us.  
 
The SAFFA study was approved by the Human Research Ethics Committee of the 
University of Cape Town.  
 
Consent for my anonymous information to be used in the SAFFA study. 
I (name of parent or legal guardian)………………………………………………………….. 
have been fully informed about the above study with its risks and benefits, and hereby 
consent for the information I share in this non-participant questionnaire to be used in the 
study. 
This consent includes the following study procedures: 
 Asking some health-related questions about my child and my family 















For illiterate parents only: 
 






I (study personnel name)………………………………………………………………, 
have fully explained the nature and purpose of the above described study with its risks 
and benefits. I have answered all the questions to the best of my ability. I will inform the 
participant of any changes in the procedures or the risks and benefits should they change 






Q1 NPID number 00000 
Q2 Questionnaire  date DD/MM/YYYY 
Q3 Study site 1 = Urban 2= Rural 
Q4 Date of birth DD/MM/YYYY 
Q5 Age at survey  XX months 
Q6 Sex 1= Male 2=Female 
Q7   You have chosen not to take part in our SAFFA study.  
Could you please tell us what your reasons are? 
1 = I don’t have enough time 
2 = I am not concerned about food allergies in my child 
3 = I do not wish my child to undergo a skin prick test 
4 = I do not wish my child to undergo any blood tests 
5 = I am not the parent or guardian and the parent is not available 
 













Q21 Food exposure 
Foods Eaten Ever Eaten Age first eaten Still eating regularly 
(once a week or 
more) 
21.1 Peanut 
e.g. peanut butter, 
peanut oil, peanuts in 


































1 = Yes 
 
 
0 = No 
21.2 Other nuts 
e.g. Cashew, 
hazelnut, brazil nut, 
almonds, walnuts, 
pistachio, macadamia 
in chocolate and 














































0 = No 
21.3 Cow’s milk products 



































1 = Yes 
 
 
0 = No 
21.4 Cow’s milk formula 









1 = yes 
 
 






















1 = Yes 
 
 
0 = No 
21.5 Soya products 








1 = yes 
 
 






















1 = Yes 
 
 
0 = No 
21.6 Soya milk products 



































1 = Yes 
 
 
0 = No 
21.7 Hen’s egg 
e.g. boiled, scrambles 
eggs, omelettes, 
quiches(souttert), 


































1 = Yes 
 
 
0 = No 
21.8 Wheat 
e.g. cereal 
(Wheetabix, All Bran, 
Tasty Wheat), bread 








1 = yes 
 
 























1 = Yes 
 
 
0 = No 




kingklip, salmon etc 
and fish products: 
Fish paste(Redro), 










1 = yes 
 
 
































0 = No 
 




Q22 Food Reactions 
22.1     PEANUTS 
22.1.1 Has your child ever had any of these reactions below to 
peanuts or food containing peanuts 
 
1 = yes 
 
0 = no 
22.1.2 If yes, which of the following reactions has this child had? (you can circle more than one) 
1= none 6= tight throat 11=shock/low blood pressure 
2= itchy Rash 7= wheeze 12= collapse/loss of consciousness 
3=swelling(face/lips/eyes) 8= vomiting 13 = worsening of eczema 
4= flushing 9= diarrhoea  
5= itchy mouth/throat 10= blue lips 

















22.1.5 If yes, was this reaction confirmed by a doctor?  
1 = yes 
 
0 = no 
 
 
22.2      OTHER NUTS 
22.2.1 Has your child ever had any of these reactions below to other 
nuts or food containing nuts other than peanuts 
 
1 = yes 
 
0 = no 
22.2.2 If yes, which of the following reactions has this child had? (you can circle more than one) 
1 = none 6 = tight throat 11 =shock/low blood pressure 
2 = itchy Rash 7 = wheeze 12 = collapse/loss of consciousness 
3 =swelling(face/lips/eyes) 8 = vomiting 13 = worsening of eczema 
4 = flushing 9 = diarrhoea  
5 = itchy mouth/throat 10 = blue lips 

















22.2.5 If yes, was this reaction confirmed by a doctor?  
1 = Yes 
 
0 = No 
 
22.3     COW’S MILK 
22.3.1 Has your child ever had any of these reactions below to cow’s 
milk or food containing cow’s milk 
 
1 = Yes 
 
0 = No 
22.3.2 If yes, which of the following reactions has this child had? (you can circle more than one) 
1 = none 6 = tight throat 11 = shock/low blood pressure 
2 = itchy Rash 7 = wheeze 12 = collapse/loss of consciousness 
3 =swelling(face/lips/eyes) 8 = vomiting 13 = worsening of eczema 
4 = flushing 9 = diarrhoea  
5 = itchy mouth/throat 10 = blue lips 

















22.3.5 If yes, was this reaction confirmed by a doctor?  
1 = Yes 
 
0 = No 




22.4    SOYA 
22.4.1 Has your child ever had any of these reactions below to soya 
or food containing soya 
 
1 = Yes 
 
0 = No 
22.4.2 If yes, which of the following reactions has this child had? (you can circle more than one) 
1 = none 6= tight throat 11=shock/low blood pressure 
2 = itchy Rash 7= wheeze 12= collapse/loss of consciousness 
3 =swelling(face/lips/eyes) 8= vomiting 13 = worsening of eczema 
4 = flushing 9= diarrhoea  
5 = itchy mouth/throat 10= blue lips 

















22.4.5 If yes, was this reaction confirmed by a doctor?  
1 = Yes 
 
0 = No 
 
 
22.5    HEN’S EGG 
22.5.1 Has your child ever had any of these reactions below to hen’s 
egg or food containing egg 
 
1 = Yes 
 
0 = No 
22.5.2 If yes, which of the following reactions has this child had? (you can circle more than one) 
1 = none 6 = tight throat 11 =shock/low blood pressure 
2 = itchy Rash 7 = wheeze 12 = collapse/loss of consciousness 
3 =swelling(face/lips/eyes) 8 = vomiting 13 = worsening of eczema 
4 = flushing 9 = diarrhoea  
5 = itchy mouth/throat 10= blue lips 

















22.5.5 If yes, was this reaction confirmed by a doctor?  
1 = Yes 
 
0 = No 
 
 
22.6     WHEAT 
22.6.1 Has your child ever had any of these reactions below to wheat 
or food containing wheat 
 
1 = Yes 
 
0 = No 
22.6.2 If yes, which of the following reactions has this child had? (you can circle more than one) 
1= none 6= tight throat 11=shock/low blood pressure 
2= itchy Rash 7= wheeze 12= collapse/loss of consciousness 
3=swelling(face/lips/eyes) 8= vomiting 13 = worsening of eczema 
4= flushing 9= diarrhoea  
5= itchy mouth/throat 10= blue lips 

















22.6.5 If yes, was this reaction confirmed by a doctor?  
1 = Yes 
 
0 = No 
 




22.7     FISH (excluding shellfish) 
22.7.1 Has your child ever had any of these reactions below to fish or 
food containing fish 
 
1 = Yes 
 
0 = No 
22.7.2 If yes, which of the following reactions has this child had? (you can circle more than one) 
1 = none 6 = tight throat 11 =shock/low blood pressure 
2 = itchy Rash 7 = wheeze 12 = collapse/loss of consciousness 
3 =swelling(face/lips/eyes) 8 = vomiting 13  = worsening of eczema 
4 = flushing 9 = diarrhoea  
5 = itchy mouth/throat 10 = blue lips 

















22.7.5 If yes, was this reaction confirmed by a doctor?  
1 = Yes 
 
0 = No 
 





Has your child ever had symptoms of asthma? 
(e.g. wheeze, persistent cough at night or when 
exercising, shortness of breath) 
 
 
1 = Yes 
 
 












If yes, who diagnosed the asthma? 
 
1 = Self 
 
2 = Nurse 
 
3 = Doctor 
 




Has your child ever had symptoms of hay fever (e.g. 
itchy runny eyes, itchy runny nose, blocked nose, 
frequent sneezing) without having a “cold” or upper 
respiratory tract infection? 
 
 
1 = Yes 
 
 













If yes, who diagnosed the hay fever? 
 
1 = Self 
 
2 = Nurse 
 






Has your child ever had symptoms of eczema (e.g. an 
itchy rash especially in the folds of the elbows, 
behinds the knees, in front of the ankles, under the 
buttocks or around the neck, ears or eyes? 
 
 
1 = Yes 
 
 













If yes, who diagnosed the eczema? 
 
1 = Self 
 
2 = Nurse 
 









Q27 Family history of allergic disease 
Does anyone in your family have allergic diseases? Please circle. 
(you can choose more than one option) 
 Family member None Asthma Hay fever Eczema Food allergy 
Q27.1 Mother 1 = none 2 = asthma 3 = hay fever 4 = eczema 5 = food allergy 
Q27.2 Father 1 = none 2 = asthma 3 = hay fever 4 = eczema 5 = food allergy 
Q27.3 Full Sibling 1 1 = none 2 = asthma 3 = hay fever 4 = eczema 5 = food allergy 
Q26.4 Full Sibling 2 1 = none 2 = asthma 3 = hay fever 4 = eczema 5 = food allergy 
Q27.5 Full Sibling 3 1 = none 2 = asthma 3 = hay fever 4 = eczema 5 = food allergy 
Q27.6 Full Sibling 4 1 = none 2 = asthma 3 = hay fever 4 = eczema 5 = food allergy 
 
Q28 Child’s Medical history 
 
Q28.1 
Does your child have any other significant medical problems? (e.g. heart or lung 
problems, kidney or liver disease, epilepsy, diabetes) 
 
1 = Yes 
 













What language do you mainly speak at home? (Please choose only one) 
1 = IsiXhosa 2 = English 3 = Afrikaans 
4 = IsiZulu 5 = Sesotho 6 = Setswana 
7 = SiSwati 8 = IsiNdebele 9=Xitsonga 




If Xhosa speaking, was this child born in Cape Town? 
 
1 = Yes 
 
0 = No 
  
If No, please complete Q 29.2 






Where was this child born? 
Province 
1 = Western Cape 
2 = Eastern Cape 
3 = Northern Cape 
4 = Free state 
5 = Gauteng 
6 = Kwazulu Natal 
7 = Mpumalanga 
8 = Limpopo 
9 = North West Province 




















Was this child’s mother born in Cape Town? 
 
1 = Yes 
 




If No, where was he/she born? 
Province (please circle) 
1 = Western Cape 
2 = Eastern Cape 
3 = Northern Cape 
4 = Free state 
5 = Gauteng 
6 = Kwazulu Natal 
7 = Mpumalanga 
8 = Limpopo 
9 = North West Province 

























What is your child’s ethnic origin? 
(circle as appropriate) 
1 = White/Caucasian 2 = Coloured / Mixed race 
3 = Black African 4 = Asian/Indian 
5 = Other (Specify) 
 
 
Q32 Parental Education level 
 
What is the highest level of education obtained by any parent of this child? 
1 = None 11 = Grade 9 / Std  7 
2 = Grade R / preschool 12 = Grade 10 / Std  8 
3 = Grade 1 / SubA 13 = Grade 11 / Std 9 
4 = Grade 2 / Sub B 14 = Grade 12 / Matric 
5 = Grade 3 / Std 1 15 = Grade 9,10,11 (Std 7,8,9) & diploma 
6 = Grade 4 / Std  2  16 = Grade 12 (Std 10) & Certificate or Diploma 
7 = Grade 5 / Std  3 17 = Grade 12 (Std 10) & Degree 
8 = Grade 6 / Std  4 18 = Grade 12 (Std 10) & Degree plus Diploma or further 
degree 
9 = Grade 7 / Std  5 19 = Grade 12 (Std 10) & PhD 




















5. General Protocol for Open Oral Food 
Challenge 
Note: Exact doses of individual foods to be challenged will be held in a separate study folder  
Q 1  Participant ID  Q4 Today’s Date  
Q 2  Date of Birth  Q5 Today’s Weight  
 
Q 3  
 
Sex  (please circle) 
 
1 = Male    2 = Female 
 
Q6 




Step 1: Pre-challenge assessment Tick when 
complete 
1. Ensure that oxygen and suction are in working order  
2. Ensure that the drug box is complete and accessible   
3. Calculate the emergency drug doses for the participants weight of today  
 
Drug Recommended dose Calculated dose for 
participant weight: ___kg 
Adrenaline 1:1000 0.01mL/kg IM  
Adrenaline neb 1:1000 0.2-0.4mL/kg adrenaline (max 
5 mL) mixed with equal 
amounts of normal saline 
 
Hydrocortisone 4mg/kg IV (max 100 mg)  
Nebulised salbutamol 2.5-5 mg  
Promethazine (Phenergan) 1mg/kg IV  
Salbutamol via MDI 6-10 puffs  
Cetirizine 2.5mg/5mg  
 
 
4. Assess if this is a high risk child (and gain IV access if needed) 
 Any symptoms of asthma within the last 4 years.  
 Any previous severe allergic reactions i.e. cardio-respiratory symptoms regardless of the allergen 
 Any child who has received adrenaline for an allergic reaction in the past. 
 
5. Ensure that the child has not had an acute exacerbation of asthma, rhinitis or eczema in the last 
2 weeks. 
(If he/she has, discuss with consultant and decide whether challenge should be postponed)  
 
6. Ensure that the child has not taken any medications that need to be stopped prior to the food 
challenge.  (see note below) 
Medication Duration to be stopped 
prior to the challenge 
 Long acting antihistamines, i.e.Cetirizine,  Loratadine, Aterax 
 Oral steroids 
5 days 
 Long acting β agonists, i.e. Serevent or Formoterol (green inhalers), Seretide(purple 
inhaler) or Symbicord (red inhaler) 
 Short acting antihistamines, i.e.Piriton, Vallergan, Phenergan 
48 hours 
 Leukotrine receptor antagonists, i.e. Montelukast or Singulair 24 hours 
                                             
 
7. Ensure that the child has not eaten (apart from sips of water) for 2 hours prior to the start of the 
challenge 
 
8. Ensure that the child is fit for challenge on brief physical examination                 
                                                                                                                                                 






 Regular preventative (steroid) inhalers, brown or orange in colour, such as Becotide should not be  stopped prior to a challenge.   
 
 Reliever inhalers may also be given, however, any child who is using their blue inhaler more frequently than normal in the tw o 
weeks prior to the challenge should discuss this with the study team before a decision is made whether or not to challenge 
them. 
 
 Combined preventative and long acting relievers, i.e. Seretide and Symbicord inhalers should be stopped and the preventative 
part of the inhaler should be commenced instead for 72 hours prior to the challenge 
 
 
Criteria for a positive challenge 
One or more of the following within 2 hours of the last dose within the food challenge 
 
 three or more concurrent non-contact hives (urticarial lesion) lasting for more than 5 min 
 Perioral or peri-orbital angioedema 
 Vomiting (excluding immediate post-ingestion gag/ vomits) 
 Circulatory compromise 
 Respiratory compromise (Wheezing, Inability to speak, Stridor, Dysphonia, Aphonia or signs 
of respiratory “distress”) 
Additional signs noted (but not positive challenge) 
 Transient urticaria (less than three hives lasting less than 5min) 
 Erythematous rashes 
 Diarrhoea 
 Abdominal pain (such as abnormal stillness or doubling over) that persists for ≥  3 minutes 
 Persistent rubbing of nose or eyes that lasts for ≥ 3 minutes 
 Persistent rhinorrhoea that lasts for ≥ 3 minutes 




Step 2: Preparation for oral food challenge Tick when 
complete 
The study nurse/doctor (and dietician if necessary) will organise both the challenge foods and any carrier foods 
on the day of admission. The foods should be labelled and dated and should be checked by 2 staff members 
prior to administration.   
 
 
The challenge food can be disguised in a food which the child eats regularly and is known to tolerate well.  
 
 Follow the challenge protocol step by step as shown in Step 3 below  
The challenge should be discontinued at any stage when a reaction occurs, and action taken where necessary.  
At each stage, a full assessment set of observations should be performed 15-20 minutes after the dose has been 
given, or immediately when there are signs of a reaction.  
 
If there has been no reaction then observe for 2 hours with half-hourly observations  
If there has been a reaction, stop the challenge and refer to Step 4   



















If YES stop challenge 




Baseline (pre-dose) observations 
Pulse        __________ 
Resp Rate__________ 
BP            __________ 









Pulse        __________ 
Resp Rate__________ 
BP            __________ 







YES/NO Pulse        __________ 
Resp Rate__________ 
BP            __________ 







YES/NO Pulse        __________ 
Resp Rate__________ 
BP            __________ 









Pulse        __________ 
Resp Rate__________ 
BP            __________ 









Pulse        __________ 
Resp Rate__________ 
BP            __________ 









Pulse        __________ 
Resp Rate__________ 
BP            __________ 









Pulse        __________ 
Resp Rate__________ 
BP            __________ 
SaO2        __________ 



















Pulse        __________ 
Resp Rate__________ 
BP            __________ 







Pulse        __________ 
Resp Rate__________ 
BP            __________ 







Pulse        __________ 
Resp Rate__________ 
BP            __________ 







Pulse        __________ 
Resp Rate__________ 
BP            __________ 








Step 4. Positive Reactions: 
Record any reactions in the table below, then follow the steps for management 















2 hour post challenge check 
 
 
3 days post challenge check 
 
 
OUTOME OF OFC: 
 
     
Mild, non-cardiorespiratory reactions (e.g. rash/angioedema) 
 The child should receive chlorpheniramine and be closely observed. 
 If the child is asthmatic, also give 10 puffs of their salbutamol inhaler via a spacer device and a dose of 
prednisone to prevent a late phase reaction.  
 The patient should be observed for at least 3 hours post challenge.  
 
Reaction involving wheeze 
 Give 15 litres of oxygen via a face mask with a reservoir bag. 
 Give a salbutamol nebulizer. 
 If ANY respiratory distress occurs give IM adrenaline. 
 Following administration of the adrenaline give a dose of chlorpheniramine and give 
hydrocortisone/prednisone to prevent late phase reaction. 
 If there is no response in 5 minutes, give a second dose of IM adrenaline and another salbutamol 
nebulizer and contact paediatric ICU for advice. 
 The patient should be observed for at least 6 hours post-reaction and admitted overnight if deemed 
necessary. 
 
Reaction involving stridor  
 Give 15 litres of oxygen via a face mask with a reservoir bag. 
 Give an adrenaline nebulizer. 
 If ANY respiratory distress occurs give IM adrenaline. 
 Following administration of the adrenaline give a dose of cetirizine or Phenergan and give 
hydrocortisone/prednisone to prevent late phase reaction. 
 If there is no response in 5 minutes, give a second dose of IM adrenaline and contact paediatric ICU.  
 The patient should be observed for at least 6 hours post-reaction and admitted overnight if deemed 
necessary. 
 
Reaction involving hypotension or collapse 
 Give IM adrenaline.  
 Gain IV access and give 20ml/kg bolus of fluid, 0.9% NaCl. 
 Give Phenergan IV, and IV hydrocortisone to prevent late phase reaction. 
 If no response in 5 minutes, repeat IM adrenaline and fast bleep an anaesthetist if not already present. 
 The patient should be observed for at least 6 hours post-reaction and admitted overnight if deemed 
necessary. 





Step 3: Oral Food Challenge: PEANUT 
Product: Black Cat peanut butter (salt and sugar free) 















If YES stop challenge 




Baseline (pre-dose) observations 
Pulse        __________ 
Resp Rate__________ 
BP            __________ 












Pulse        __________ 
Resp Rate__________ 
BP            __________ 









YES/NO Pulse        __________ 
Resp Rate__________ 
BP            __________ 









YES/NO Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 






















Pulse        __________ 
Resp Rate__________ 
BP            __________ 







Pulse        __________ 
Resp Rate__________ 
BP            __________ 







Pulse        __________ 
Resp Rate__________ 
BP            __________ 
SaO2        __________ 






Pulse        __________ 
Resp Rate__________ 
BP            __________ 







Pulse        __________ 
Resp Rate__________ 
BP            __________ 
SaO2        __________ 
 
 





Step 3: Oral Food Challenge: RAW EGG WHITE 
Raw egg white (total eqw 60g egg) 














If YES stop challenge 




Baseline (pre-dose) observations 
Pulse        __________ 
Resp Rate__________ 
BP            __________ 













Pulse        __________ 
Resp Rate__________ 
BP            __________ 









YES/NO Pulse        __________ 
Resp Rate__________ 
BP            __________ 









YES/NO Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 












Pulse        __________ 
Resp Rate__________ 
BP            __________ 

















Pulse        __________ 
Resp Rate__________ 
BP            __________ 







Pulse        __________ 
Resp Rate__________ 
BP            __________ 







Pulse        __________ 
Resp Rate__________ 
BP            __________ 
SaO2        __________ 













Pulse        __________ 
Resp Rate__________ 
BP            __________ 







Pulse        __________ 
Resp Rate__________ 
BP            __________ 
SaO2        __________ 




















If YES stop challenge 




Baseline (pre-dose) observations 
Pulse        __________ 
Resp Rate__________ 
BP            __________ 












Pulse        __________ 
Resp Rate__________ 
BP            __________ 












Pulse        __________ 
Resp Rate__________ 
BP            __________ 












Pulse        __________ 
Resp Rate__________ 
BP            __________ 












Pulse        __________ 
Resp Rate__________ 
BP            __________ 












Pulse        __________ 
Resp Rate__________ 
BP            __________ 












Pulse        __________ 
Resp Rate__________ 
BP            __________ 












Pulse        __________ 
Resp Rate__________ 
BP            __________ 
SaO2        __________ 




















Pulse        __________ 
Resp Rate__________ 
BP            __________ 








Pulse        __________ 
Resp Rate__________ 
BP            __________ 








Pulse        __________ 
Resp Rate__________ 
BP            __________ 








Pulse        __________ 
Resp Rate__________ 
BP            __________ 
























If YES stop challenge 




Baseline (pre-dose) observations 
Pulse        __________ 
Resp Rate__________ 
BP            __________ 












Pulse        __________ 
Resp Rate__________ 
BP            __________ 












Pulse        __________ 
Resp Rate__________ 
BP            __________ 












Pulse        __________ 
Resp Rate__________ 
BP            __________ 












Pulse        __________ 
Resp Rate__________ 
BP            __________ 












Pulse        __________ 
Resp Rate__________ 
BP            __________ 












Pulse        __________ 
Resp Rate__________ 
BP            __________ 












Pulse        __________ 
Resp Rate__________ 
BP            __________ 
SaO2        __________ 




















Pulse        __________ 
Resp Rate__________ 
BP            __________ 








Pulse        __________ 
Resp Rate__________ 
BP            __________ 








Pulse        __________ 
Resp Rate__________ 
BP            __________ 








Pulse        __________ 
Resp Rate__________ 
BP            __________ 

























If YES stop challenge 




Baseline (pre-dose) observations 
Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 









YES/NO Pulse        __________ 
Resp Rate__________ 
BP            __________ 









YES/NO Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 






















Pulse        __________ 
Resp Rate__________ 
BP            __________ 







Pulse        __________ 
Resp Rate__________ 
BP            __________ 







Pulse        __________ 
Resp Rate__________ 
BP            __________ 
SaO2        __________ 






Pulse        __________ 
Resp Rate__________ 
BP            __________ 







Pulse        __________ 
Resp Rate__________ 
BP            __________ 
SaO2        __________ 





















If YES stop challenge 




Baseline (pre-dose) observations 
Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 









YES/NO Pulse        __________ 
Resp Rate__________ 
BP            __________ 









YES/NO Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 






















Pulse        __________ 
Resp Rate__________ 
BP            __________ 







Pulse        __________ 
Resp Rate__________ 
BP            __________ 







Pulse        __________ 
Resp Rate__________ 
BP            __________ 
SaO2        __________ 






Pulse        __________ 
Resp Rate__________ 
BP            __________ 







Pulse        __________ 
Resp Rate__________ 
BP            __________ 
SaO2        __________ 





















If YES stop challenge 




Baseline (pre-dose) observations 
Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 









YES/NO Pulse        __________ 
Resp Rate__________ 
BP            __________ 









YES/NO Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
BP            __________ 











Pulse        __________ 
Resp Rate__________ 
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Parent Information on Food Challenge 
Dear Parent 
The results of the allergy tests in your child suggest that he/she may have a food allergy. 
However, we are not sure of this so we need to find out for sure by doing a food 
challenge.  
 
What is a Food Challenge? 
In a food challenge we bring the child in to hospital for the day and give them small 
amounts of the food to which they had a positive allergy test, to see if there is any 
reaction. This is done in a very controlled way and the doctors and nurses will be there 
with you and your child to watch them closely. That way we can notice reactions early 
and treat them if needed. 
 
If the child has no reactions to a very tiny amount of the food, then we will give them a 
little more, step by step, until we reach the top dose. The top dose will be similar to a 
normal “portion” of the food, for example about 1 tablespoon of  peanut butter or one 
cupful of milk. In between each dose we will gently examine the child to look for any 
reactions, and also measure the temperature, pulse rate, heart rate, blood pressure and 
oxygen levels.  
 
If there are any reactions along the way, we will stop the food challenge and treat the 
child if necessary. 
 
We will then give you the correct advice on the food in the child’s diet according to the 
results of the challenge. 
 
The doctor will also phone you at home after 2 days to make sure everything is alright 
and to ask if the child’s eczema has got any worse.  
 
How long will the challenge take? 
You and your child will need to be in hospital for at least a whole morning. Giving the 
doses of food takes up to 2 hours because we leave a 20 minute gap between each dose. 




After the challenge, we will keep an eye on the child for at least 2 hours if there has been 
no reaction. This is to be safe that the child remains well and that there are no “late 
reactions.” 
 
If there has been a reaction, we will keep an eye on your child for at least 4 hours until we 
are happy that all is well. Sometimes, if children have had a bad reaction, we may decide 
it is better to keep them in hospital overnight. However, this is very rare. 
 
Will it hurt my child? 
The actual food challenge is not painful in any way. Some children may be a bit 
frightened of having their temperature and pulse e.t.c. taken but it is not sore.  
In a few children who are at higher risk of a reaction, especially those with asthma, we 
may consider putting a drip up before the challenge. We will only do this if absolutely 
necessary. 
 
If children have a reaction during the challenge, the doctors and nurses will be right there 
to treat the child as quickly as possible. Most reactions are mild, such as rashes, and the 
child may need to take some antihistamine syrup. A few children will have more severe 
reactions, and these children may need an injection or even a drip.  
 
We do not expect this in many children at all because we start off with such small doses 
of food and watch the children so carefully.  
 
What do you need to do? 
 
1. Your child will need to be off some of their regular medications for up to a week 
before the challenge. Your doctor will give you details of these below: 
Medication…………………….When to stop………………………………… 
 
Medication…………………….When to stop………………………………… 
 
Medication…………………….When to stop………………………………… 




2. If your child has been unwell in the 2 weeks before the challenge, please let the study 
doctor know a few days before the challenge so that we can decide whether we need 
to postpone the challenge. The doctor or nurse will also phone you 2 days before the 
challenge to make sure all is well. 
 
3. We will ask you to come to the paediatric allergy clinic at 8.30 on the morning of the 
challenge. We will then ask a few questions to make sure all is well, have a quick look 
at the child and take their observations such as temperature and pulse. We will aim to 
start the actual challenge by 9 am.  
 
4. On the morning of the challenge, your child can have their regular milk and/or a light 
breakfast between 6 and 7 am. After that they should not eat or drink anything 
(except a few sips of water) before the challenge. 
 
5. We may ask you to bring along some of the child’s favourite food or regular milk so 
that we can mix the test food into it for the child to eat.  
 
6. Please dress the child in comfortable clothes that are easy to lift up for examining the 
child. 
 
7. Bring along any favourite toys/dummies/blankets. It is a long morning for the children 
and we would like to make it as nice as possible for them! 
 
8. We will give you travel money once you are in hospital for the challenge.  
 
Thank you 
If you have any questions or concerns at any stage about the food challenge, please 
contact: Dr Maresa Botha on 0216585779  
 




6. Checklists and Data Capture Sheets 
DATA CAPTURE SHEET 1 
 









Q3 Study site 1 = Urban 2= Rural 
Q4 Date of birth DD/MM/YYYY 
Q5 Age at enrolment XX years  XX months 
Q6 Sex 1= Male 2=Female 
 
 
Crèche visit activity checklist       (please circle) 
Consent to SAFFA study Yes/No If No, please complete non-participant questionnaire 
Consent form copy given to parents Yes/No  
Questionnaire completed Yes/No 
Physical examination completed Yes/No 
Skin Prick Test completed Yes/No 
Need further investigation/OFC? Yes/No If Yes, 
 Was appointment booked at RXH? Yes/No 
 Was parent given OFC information? Yes/No 
 Appointment Date:  
 
 
Hospital Visit Activity Checklist                              (please circle) 
Consent form for OFC and other tests Yes/No  
Information and consent form given to 
parents? 
Yes/No  
Skin Prick test Yes/No  
Blood sample Yes/No  
Stool sample Yes/No  
Oral Food Challenge completed and 
conclusive 
Yes/No If not conclusive,  
 Was repeat appointment booked? 
Yes/No 
 Appointment Date:  
 
FINAL RESULT YES  NO  
Sensitised (SPT≥1mm) a b 
Oral food challenge indicated (SPT≥1mm) c d 
 
 
Study Complete: Yes/No 
 
Data Entry Complete: Yes/No 




Crèche Visit: Physical Examination:    Date_______ Examined by _____ 
 
Question 6: Anthropometric measures 
Q 6.1     Height cm                                       Q 6.2   Weight                               kg 
Q 6.3 Abdominal girth cm Q6.4 Skin fold thickness cm 
 
Question 7: Physical examination 
Q 7.1 Allergic Rhinitis   Yes/No                              
(tick√) 
Q 7.2 Eczema                  Yes/No                              
(tick√) 
Q 7.3 Asthma Yes/No                                     
(tick√) 
Sneezing  Facial pallor  Tachypnoea(>40/min)  
Itchy nose  Facial erythema  Hyperinflation  
Transverse nasal crease  Hypo pigmented 
patches 
 Prolonged Expiration  
Allergic salute  Infra orbital folds 
(Dennie-Morgan folds) 
 Wheeze  
Rhinorrhoea/discharge  Angular cheilitis   
Nasal congestion  Anterior neck folds  
Mouth Breathing  Flexor involvement  
Oedematous turbinates  Extensor patches  
“long face syndrome”  Darkening lesions  
Red eyes  Lichenification  
Itchy eyes   
Teary eyes/discharge  
Post –nasal drip (Clicking)  
 
Crèche Visit:  Skin Prick Test results: Date_______ Done By_____ 
 
Anti-histamine taken? Yes/No              When last? ________________________ 
 
Batch Numbers 
Negative  Fish(cod)  
Egg White  Peanut  
Cow’s Milk  Hazelnut  
Soy  Positive  
Wheat   
 




X mm Y mm Mean (mm) 
8.1 Negative    
8.2 Egg White    
8.3 Cow’s Milk    
8.4 Soy    
8.5 Wheat    
8.6 Fish(cod)    
8.7 Peanut    
8.8 Hazelnut    
8.9 Positive    
 Fresh Agent   
8.10 Fresh Peanut    Comments 
8.11 Egg White    
8.12 Cow’s Milk    




DATA CAPTURE SHEET 2 
 
Blood specimen:  Sample obtained: Yes/No 
Food specific IgE levels kU/L 
Egg White  
Cow’s milk  
Soy  
Wheat  




Ascaris specific IgE  
 
Serum stored:  Yes/No 
 
Stool:   Sample obtained: Yes/No 
 
Worm Ova Present:   Yes: ___________ No: ____________        If Yes:  
 
Type Yes No Quantity 
(epg) 
Burden of infestation 
(Light/moderate/heavy) 
A.lumbricoides     
T. trichiuria     
Hookwurm     
S. japonicum 
S. mansoni 
    
  
Stool sample stored: Yes/no 
 





House Dust mite Negative Scanty Well represented Heavy infestation 
ELISA 
Dog   
Cat   
House Dust Mite DerP1   
Cockroach   
Peanut Allergen   
Endotoxin   
 
Dust sample stored: Yes/No 
 




DATA CAPTURE SHEET 3 
 
ORAL FOOD CHALLENGE:  
Study no: ________________________ 
Initials___________________________DOB_____________________________ 





TESTED? Result if tested 
Positive Equivocal Negative 
Hen’s egg 
(raw) 
Yes    
No    
Hen’s egg 
(cooked) 
Yes    
No    
Cow’s milk Yes    
No    
Soya milk Yes    
No    
Peanut butter Yes     
No    
Hake Yes    
No    
Wheat Yes    
No    
Tree nuts Yes    








If result equivocal, Was OFC rebooked: Yes__________________ No _________________ 
 
Date of new booking: __________________________ 
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7.1 Study Summary 
Title 
A cross-sectional study of Ig-E mediated food sensitisation and food allergy in an 
unselected population of South African children aged 12-36 months. 
Background 
Food allergies have been described as the new allergy epidemic in recent literature from 
resource rich settings with a prevalence of up to 10% in the 1st year of life. In South Africa 
there has been documentation over the last few years of an increase in the prevalence of 
allergic disease in population groups believed to be protected.  
Objectives 
4. To determine the sensitisation levels and challenge-proven prevalence to any one or 
more of the 7 common allergic foods (hen’s egg, cow’s milk, peanut, tree nuts, soy, 
wheat and fish) in children aged between 12-36 months. 
Methodology  
A sampling frame of all crèches in Cape Town will be used to randomly select crèches. A 
participant questionnaire and skin prick tests will be used to collect data from children 
enrolled into the study. Those who qualify will be invited for food challenges. 
Envisaged outcomes 
To determine the true prevalence of food allergy in a rapidly urbanising context for 
issues of advocacy regarding health service provision, availability of safe and affordable 
alternative foods particularly in resource poor communities. 
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